

Profiles  
March 10, 2016

**DAVID LOUIS DUNNER, M.D.**  
**LIST OF PUBLICATIONS**

1. Heilman DH, Bernton HW, Dunner DL, and Barber SM: Acid fastness of pine pollen. Stain Techn., 38:193-197, 1963.
2. Chang PL, Dunner DL, Harding J, and Sun DC: An improved technique for tubeless gastric analysis. Amer. J. Gastroent., 42:165-171, 1964.
3. Cohn CK, Dunner DL, and Axelrod J: Reduced catechol-O-methyltransferase activity in red blood cells of women with primary affective disorder. Science, 170:1323-1324, 1970.
4. Dunner DL, Brodie HKH, and Goodwin FK: Plasma DOPA response to levodopa administration in man: effects of a peripheral decarboxylase inhibitor. Clin. Pharmacol, Ther., 12:212-217, 1971.
5. Goodwin FK, Dunner DL, and Gershon ES: L-DOPA: effect on brain serotonin metabolism in depressed patients. Life Sci., 10, (Part 1):751-759, 1971.
6. Gershon ES, Dunner DL, and Goodwin FK: Toward a biology of affective disorders: genetic contributions. Arch. Gen. Psychiat. 25:1-15, 1971.
7. Gershon ES, Bunney WE Jr., Goodwin FK, Murphy DL, Dunner DL, and Henry GM: Catecholamine and Affective Illness: Studies with L-DOPA and Alpha- Methyl-Para-

- Tyrosine. In Brain Chemistry and Mental Disease, Ho BT and McIssac WM. New York, Plenum Press, pp. 135-161, 1971.
8. Dunner DL, Cohn DK, Gershon ES, and Goodwin FK: Differential catechol-o-methyltransferase activity in unipolar and bipolar affective illness. Arch. Gen. Psychiat. 25:348-353, 1971.
  9. Dunner DL, Gershon ES, Goodwin GK, Murphy DL, and Bunney WE Jr.: Excretion of 17-hydroxycorticosteroids in unipolar and bipolar depressed patients. Arch. Gen. Psychiat. 26:360-363, 1972.
  10. Dunner DL and Goodwin FK: The effect of l-tryptophan on brain serotonin metabolism in depressed patients. Arch. Gen. Psychiat. 26:364-366, 1972.
  11. Goodwin FK, Murphy DL, Dunner DL, and Bunney WE, Jr.: Lithium response in unipolar versus bipolar depression. Amer. J. Psychiat. 129:44-47, 1972.
  12. Fieve RR, Meltzer H, Dunner DL, Levitt M, Mendlewicz J, and Thomas A: Rubidium: biochemical, behavioral, and metabolic studies in humans. Amer. J. Psychiat. 130:55-61, 1973.
  13. Goodwin FK, Post RM, Dunner DL, and Gordon EK: Cerebro-spinal fluid amine metabolites in affective illness: the pro-benecid technique. Amer. J. Psychiat. 130:73-79, 1973.
  14. Dunner DL, Cohn DK, Weinschilboum RM, and Wyatt RJ: The activity of dopamine-beta-hydroxylase and methionine-activating enzyme in blood of schizophrenic patients. Biological Psych. 6:215-220, 1973.
  15. Gershon ES, Dunner DL, Sturt L, and Goodwin FK: Assortative mating in the affective disorders. Biol. Psychiat. 7, 63-74, 1973.

16. Baker M, Hadler NM, Whitaker JM, Dunner DL, Gerwin RD, and Decker JL: Psychopathology in systemic lupus erythematosus. II. Relation to clinical observations, corticosteroid administration, and cerebrospinal fluid C<sub>4</sub>. Semin. Arthritis, Rheum. 3:111-126, 1973.
17. Dunner DL and Fieve RR: Clinical factors in lithium carbonate prophylaxis failure. Arch. Gen. Psychiat. 30:229-233, 1974.
18. Perel JM, Levitt M, and Dunner DL: Plasma and cerebrospinal fluid probenecid concentration as related to accumulation of acidic biogenic amine metabolites in man. Psychopharmacologia (Berl.) 35:83-90, 1974.
19. Dunner DL, Meltzer HL, and Fieve RR: Cerebrospinal fluid rubidium metabolism in depression. Psychopharmacologia (Berl.) 37:7-13, 1974.
20. Dunner DL and Fieve, RR: Affective disorder: Studies with amine precursors. Amer. J. Psychiat. 132:180-183, 1975.
21. Dunner DL, Meltzer, HL, Schreiner JC, and Feigelson JL: Plasma and erythrocyte magnesium levels in patients with primary affective disorder during chronic lithium treatment. Acta Psychiat. Scand. 51:104-109, 1975.
22. Fieve RR and Dunner DL: Unipolar and bipolar affective states. In The Nature and Treatment of Depression, Flach FF and Draghi SC (Eds), pp. 145-166, New York, John Wiley and Sons, Inc., 1975.
23. Dunner DL and Fieve RR: Psychiatric illness in fathers of men with bipolar primary affective disorder. Arch. Gen. Psychiat. 32:1134-1137, 1975.

24. Fieve RR, Dunner DL, Kumbaraci T, and Stallone F: Lithium carbonate in affective disorders IV: A double-blind study of prophylaxis in unipolar recurrent depression. Arch. Gen. Psychiat., 32:1541-1544, 1975.
25. Fleiss J, Dunner DL, Stallone F, and Fieve RR: The life table: a method of analysis of longitudinal data. Arch. Gen. Psychiat., 33:106-122, 1976.
26. Dunner DL, Stallone F, and Fieve RR: Lithium carbonate and affective disorders: V. A double-blind study of prophylaxis of depression in bipolar illness. Arch. Gen. Psychiat., 33:117-120, 1976.
27. Levitt J, Dunner DL, Mendlewicz J, Frewin D, Lawlor W, Fleiss J, Stallone F, and Fieve RR: Plasma dopamine B hydroxylase activity in affective disorder. Psychopharmacologia (Berl) 46:205-210, 1976.
28. Dunner DL, Gershon ES, and Goodwin FK: Heritable factors in the severity of affective illness. Biol. Psychiat. 11:31-42, 1976.
29. Dunner DL, Fleiss JL, Addonizio G, and Fieve RR: Assortative mating in primary disorder. Biol. Psychiat. 11:44-52, 1976.
30. Kuyler PL and Dunner DL: Psychiatric disorders and the need for mental health services among a sample of orthopedic inpatients. Compr. Psychiat. 17:395-400, 1976.
31. Dunner DL, Dywer T, and Fieve RR: Depressive symptoms in patients with unipolar and bipolar affective disorder. Compr. Psychiat. 17:447-451, 1976.

32. Fieve RR, Dunner DL, Kumbaraci T, and Stallone F: Lithium carbonate prophylaxis of depression in three subtypes of primary affective disorder. Pharmako Psychiatrie Neuropsychopharmakologie 9:100-107, 1976.
33. Farkas T, Dunner DL, and Fieve RR: L-Tryptophan in depression. Biol Psychiat. 11:295-302, 1976.
34. Fieve RR, Milstoc M, Kumbaraci T, and Dunner DL: The effect of lithium on red blood cell cholinesterase activity in patients with affective disorders. Dis. Nerv. Syst. 37:240-243, 1976.
35. Dunner DL, Fleiss JL, and Fieve RR: Lithium carbonate prophylaxis failure. Brit J. Psychiat. 129:40-44, 1976.
36. Diamond SB, Rubinstein AA, Dunner DL, and Fieve RR: Menstrual problems in women with primary affective illness. Compr. Psychiat. 17:541-548, 1976.
37. Fieve RR, Kumbaraci T, and Dunner DL: Lithium prophylaxis of depression in bipolar I, bipolar II and unipolar patients. Amer. J. Psychiat. 133:925-929, 1976.
38. Dunner DL, Fleiss JL, and Fieve RR: The course of development of mania in patients with recurrent depression. Amer. J. Psychiat. 133:905-908, 1976.
39. Dempsey GM, Dunner DL, Fieve RR, Farkas T, and Wong J: Treatment of excessive weight gain in patients taking lithium. Amer. J. Psychiat. 133:1082-1084, 1976.
40. Dunner DL and Somervill JW: "Medical Treatments" in Abnormal Psychology, Rimm, DC and Somervill JW, eds. New York Academic Press, pp. 591-614, 1977.

41. Dunner DL, Levitt M, Kumbaraci T, and Fieve RR: Erythrocyte catechol-o-methyltransferase activity in primary affective disorder. Biol. Psychiat. 12:237-244, 1977.
42. Gross HA, Dunner DL, Lafleur D, Meltzer HL, and Fieve RR: Prostaglandin F in patients with primary affective disorder. Biol. Psychiat. 12:347-357, 1977.
43. Hall KS, Dunner DL, Zeller G, and Fieve RR: Bipolar illness: A prospective study of life events. Comp. Psychiat. 18:497-502, 1977.
44. Dunner DL, Patrick V, and Fieve RR: Rapid cycling manic depressive patients. Comp. Psychiat. 18:561-566, 1977.
45. Gross HA, Dunner DL, Lafleur D, Meltzer HL, Muhlbauer HL, Fieve RR: Prostaglandin: A review of neurophysiology and psychiatric implications. Arch. Gen. Psychiat. 34:1189-1196, 1977.
46. Dunner DL, Heiber S, and Perel JM: The effect of L-tryptophan administration on the concentration of probenecid in plasma and cerebrospinal fluid in patients. Psychopharmacology 53:305-308, 1977.
47. Meltzer HL, Kassir S, Dunner DL, and Fieve RR: Repression of a lithium pump as a consequence of lithium ingestion in manic depressive subjects. Psychopharmacology 54:113-118, 1977.
48. Kim YB, Dunner DL, Meltzer HL and Fieve RR: Lithium Erythrocyte: plasma ratio in primary affective disorder. Comp. Psych. 19:123-134, 1978.

49. Barkai AI, Dunner DL, Gross H, Mayo P, and Fieve RR: Reduced myoinositol levels in cerebrospinal fluid from patients with affective disorder. Biol Psychiat. 13:65-72, 1978.
50. Dunner DL and Fieve RR: The Lithium ion: Its impact on diagnostic practice. In Psychiatric Diagnosis: Exploration of Biological Predictors, Akiskal HS and Webb WL, eds. Spectrum Publications, Inc., New York, 1978, pp. 233-246.
51. Fleiss JL, Prien RF, Dunner DL, and Fieve RR: Actuarial studies of the course of manic-depressive illness. Compr. Psychiatry 19:355-362, 1978.
52. Dunner DL, Meltzer HL, and Fieve RR: Metabolism of lithium in erythrocytes. McLean Hosp. J. 3:89-97, 1978.
53. Dunner DL, Meltzer HL, and Fieve RR: Clinical correlates of the lithium pump. Amer. J. Psychiat. 135:1062-1064, 1978.
54. Patrick V, Dunner DL, and Fieve RR: Life events and primary affective illness. Acta Psychiatr. Scand. 58:48-55, 1978.
55. Dunner DL and Fieve RR: The effect of lithium in depressive subtypes. Neuropsychopharmacology, P. Deniker, C. Radouco-Thomas, and Al Villeneuve, eds. Pergamon Press, New York, 1109-1115, Vol. 2.
56. Dunner DL, Igel GJ, and Fieve RR: Social adjustment in primary affective disorder. Amer. J. Psychiat. 135:1413-1413, 1978.
57. Ruestow P, Dunner DL, Bleecker B, and Fieve RR: Marital adjustment in primary affective disorder. Compr Psychiatry 19:565-571, 1978.

58. Cho JT, Bone S, Dunner DL, Colt E, and Fieve RR: The effect of lithium treatment on thyroid function in patients with primary affective disorder. Amer. J. Psychiat. 136:115-116, 1979.
59. Schreiner HC, Dunner DL, Meltzer HL, and Fieve RR: The relationship of the lithium erythrocyte: plasma ratio to plasma lithium level. Biol. Psychiat. 14:207-213, 1979.
60. Dunner DL, Patrick V, and Fieve RR: Life events at the onset of bipolar affective illness. Amer. J. Psychiat. 136:508-511, 1979.
61. Dunner DL, Hensel BM, and Fieve RR: Bipolar illness: Factors in drinking behavior. Amer. J. Psychiat. 137:583-584, 1979.
62. Roose SP, Nurnberger JI, Dunner DL, Blood DK, and Fieve RR: Cardiac sinus node dysfunction during lithium treatment. Amer. J. Psychiat. 136:804-807, 1979.
63. Roose SP, Bone S, Haidorfer C, Dunner DL, and Fieve RR: Lithium treatment in older patients. Amer. J. Psychiat. 136:843-844, 1979.
64. Asnis GM, Asnis D, Dunner DL, and Fieve RR: Cogwheel rigidity during chronic lithium therapy. Amer. J. Psychiat. 136:1225-1226, 1979.
65. Colt EWD, Igel G, Fieve RR, and Dunner DL: Lithium associated nephropathy. Amer. J. Psychiat. 136:1098-1099 (letter to ed.), 1979.
66. Liebowitz MR, Stallone F, Dunner DL, and Fieve RR: Personality features of patients with primary affective disorder. Acta Psychiat. Scand. 60:214-224, 1979.

67. Hensel B, Dunner DL, and Fieve RR: The relationship of family history of alcoholism to primary affective disorder. J. Affective Dis. 1:105-113, 1979.
68. Rosenthal NE, Rosenthal LN, Stallone F, Fleiss J, Dunner DL, and Fieve RR: Psychosis as a predictor of response to lithium maintenance treatment in bipolar affective disorder. J. Affective Dis. 1:237-245, 1979.
69. Dunner DL, Murphy D, Stallone F, and Fieve RR: Episode frequency prior to lithium treatment in bipolar manic depressive patients. Compr. Psychiat. 20:511-515, 1979.
70. Dunner DL and Fieve RR: Catecholamine metabolizing enzymes and primary affective disorders. In Catecholamine: Basic and Clinical Frontiers, Usdin E, Kopin IJ, and Barchas J, eds. Pergamon Press, New York, pp. 1908-1910, 1979.
71. Nurnberger J, Roose SP, Dunner DL, and Fieve RR: Unipolar mania: A distinct clinical entity. Amer. J. Psychiat. 136:1420-1423, 1979.
72. Dunner DL, Meltzer HL, and Fieve RR: "Clinical aspects of lithium efflux from erythrocytes" in Biological Psychiatry Today, Obiols J, Ballus C, Bonzales Monclus E, and Pujol J, eds. Amsterdam, Elsevier/North Holland Biomedical Press, pp. 1148-1152, 1979.
73. Fieve RR, Meltzer HL, Dunner DL, and Fleiss JL: "Lithium pump repression as an indicator of prophylactic response" in Biological Psychiatry Today, Obiols J, et al, eds., Amsterdam Elsevier/North Holland Biomedical Press, pp. 1123-1127, 1979.
74. Dunner DL and Rosenthal NE: "Schizoaffective states" The Psychiatric Clinics of North America 2:441-448, 1979.

75. Dunner DL: Rapid cycling bipolar manic depressive illness. The Psychiatric Clinics of North America 2:461-467, 1979.
76. Goodnick PJ, Meltzer HL, Dunner DL, and Fieve RR: Repression and reactivation of lithium efflux from erythrocytes. Psychiat. Res. 1:147-152, 1979.
77. Fieve RR, Meltzer HL, Dunner DL, and Fleiss JL: "Lithium pump repression as an indicator of prophylactic response" in Lithium/controversies and unresolved issues, Cooper TB, Gerson S, Kline NS, and Schou M, eds., Excerpta Medica, Amsterdam 1979, pp. 257-261.
78. Dunner DL, Roose SP, and Bone S: "Complications of lithium treatment in older patients" in Lithium/controversies and unresolved issues, Cooper TB, Gershon S, Kline NS, and Schou M, eds., Excerpta Medica, Amsterdam, pp. 427-431, 1979.
79. Fieve RR, Meltzer HL, Dunner DL: "Clinical trials with rubidium chloride in depressed patients" in Biological Psychiatry Today, Obiols J, Ballus C, Gonzales Monclus E, and Pujol J, eds. Amsterdam Elsevier/North Holland Biomedical Press, pp. 1128-1131, 1979.
80. Bone S, Roose SP, Dunner DL, and Fieve RR: Incidence of side effects in patients on long-term lithium treatment. Amer. J. Psychiat. 137:103-104, 1980.
81. Georgotas A, Dunner DL, Meltzer HL, Solomon F, Fieve RR, and Gerson S: The importance of dietary control in metabolic studies of manic-depressive patients. Biol. Psychiat. 15:157-163, 1980.
82. Goodnick PJ, Perel JM, Dunner DL, and Fieve RR: CSF CAMP in primary affective disorder: Effects of probenecid and tryptophan. Biol Psychiat. 15:173-176, 1980.

83. Gwirtsman HE, Meltzer HL, Dunner DL, Fieve RR, and Pierson RN, Jr.: Rubidium replacement of total body potassium in humans. Hormone and Metabolic Research 12:175, 1980.
84. Fieve RR, Kumbaraci T, Kassir S, Dunner DL, and Cote L: Platelet monoamine oxidase activity in affective disorder. Biol. Psychiat. 15:473-478, 1980.
85. Cohen D and Dunner DL: "The assessment of cognitive dysfunction in dementing illness" in Psychopathology in the aged, Cole JO and Barrett JE, eds. Raven Press, New York, 1980, pp. 123-135.
86. Goodnick PJ, Evans HE, Dunner DL, and Fieve RR: Amino acid concentrations in cerebrospinal fluid: Effects of aging, depression, and probenecid. Biol.Psychiat. 15:557-563, 1980.
87. Kuyler PL, Rosenthal L, Igel G, Dunner DL, and Fieve RR: Psychopathology among children of manic-depressive patients. Biol. Psychiat. 15:589-597, 1980.
88. Rosenthal NE, Rosenthal LN, Stallone F, Dunner DL, and Fieve RR: Toward the validation of RDC schizoaffective disorder. Arch. Gen. Psychiat. 37:804-810, 1980.
89. Peselow ED, Gulbenkian G, Dunner DL, Fieve RR, and Burdock EI: Lithium, tricyclics and lithium, and tricyclics in the prophylaxis of unipolar illness. IRCS Medical Science 8:524-525, 1980.
90. Stallone F, Dunner DL, Ahearn J, and Fieve RR: Statistical predictions of suicide in depressives. Compr. Psych. 21:381-387, 1980.
91. Peselow ED, Dunner DL, Fieve RR, and Lautin A: Lithium carbonate and weight gain. J. Affect. Dis. 2:303-310, 1980.

92. Dunner DL: Unipolar and bipolar depression: Recent findings from clinical and biological studies. The Psychobiology of Affective Disorders, Mendels J and Amsterdam JD, eds., S. Karger-Basel, pp. 11-24, 1980.
93. Dunner DL and Hall KS: Social adjustment and psychological precipitants in mania. Mania: An Evolving Concept, Belmaker RH and van Praag HM (eds), Spectrum Publications, New York. pp. 337-347, 1980.
94. Fieve RR, Meltzer HL, Dunner DL: Ensayo critico con cloruro de rubidio en pacientes deprimidos. Rev. Depart. Psiquatria Facult. Med. Baran, 7:447-452, 1980.
95. Colt EWD, Dunner DL, Hall K, and Fieve RR: A high prevalence of affective disorder in runners, in Psychology of Running, Sacks MH and Sachs ML, eds., Human Kinetics Pub. Inc., Champaign, Ill. pp. 234-248, 1981.
96. Dunner DL: Affective Disorders. Current Therapy, Conn HF (ed.), WB Saunders Co., Philadelphia, PA, pp. 956-965, 1981.
97. Goodnick PJ, Fieve RR, Meltzer HL, and Dunner DL: Lithium elimination half-life and duration of therapy. Clin. Pharm. Therapy. 29:47-60, 1981.
98. Peselow ED, Dunner DL, Fieve RR, and Lautin A: Prophylactic effect of lithium against depression in cyclothymic patients: A life table analysis. Compr. Psychiat. 22:257-264, 1981.
99. Dealy RS, Ishiki DM, Avery DA, Wilson LG, and Dunner DL: Secondary depression in anxiety disorders. Compr. Psychiat. 22:612-618, 1981.

100. Goodnick PJ, Dunner DL, and Fieve RR: Bipolar II - A distinct diagnostic entity? Isr. J. Psychiat. Relat. Sci. 18:221-227, 1981.
101. Bone S, Roose SP, Dunner DL, and Fieve RR: Bioavailability of lithium carbonate: single versus multiple daily dosing. J. Clin. Psychopharm. 1:390-391, 1981.
102. Goodnick RJ, Meltzer HL, Fieve RR, and Dunner DL: Differences in lithium kinetics between bipolar and unipolar patients. J. Clin. Psychopharm. 2:48-50, 1982.
103. Peselow ED, Gulbenkian G, Dunner DL, Fieve RR, and Deutsch SI: Relationship between plasma lithium levels and prophylaxis against depression in bipolar I, bipolar II, and cyclothymic patients. Compr. Psychiat. 23:176-180, 1982.
104. Dunner DL, Russek RD, Russek B, and Fieve RR: Classification of affective disorder subtypes. Compr. Psychiat. 23:186-189, 1982.
105. Wilson LG, Rosenthal NE, and Dunner DL: The phenomenology of Bipolar I manic depressive illness. J. Canadian Psychiatry 27:150-154, 1982.
106. Colt EWD, Dunner DL, Wang J, Ross DC, Pierson RN, and Fieve RR: Body composition in affective disorders before, during and after lithium carbonate therapy. Arch. Gen. Psychiat. 39:577-581, 1982.
107. Dunner DL: High risk studies in affective disorders, in Biological Markers in Psychiatry and Neurology, Usdin E and Handin I, eds., New York, Pergamon Press, pp. 3-11, 1982.
108. Peselow ED, Dunner DL, Fieve RR, and Lautin A: Lithium prophylaxis of depression in unipolar, bipolar II, and cyclothymic patients. Amer. J. Psychiat. 139:747-752, 1982.

109. Dunner DL, Stallone F, and Fieve RR: Prophylaxis with lithium carbonate: an update. Arch Gen. Psychiatry 39:1344-1345, 1982 (letter to editor).
110. Beitman BD and Dunner DL: L-Tryptophan in the maintenance treatment of bipolar II manic depressive illness. Amer. J. Psychiat. 139:1498-99, 1982.
111. Goodnick PJ, Fieve RR, Meltzer HL, and Dunner DL: Lithium pharmacokinetics, duration of therapy, and the adenylate cyclase system. Int. Pharmacopsychiat. 17:65-72, 1982.
112. Peselow ED, Dunner DL, Fieve RR, Deutsch SE, and Rubinstein ME: Age of onset of affective illness. Psychiatria Clin. 15:124-132, 1982.
113. Dunner DL: Lithium treatment of the aged in Treatment of Psychopathology in the Aging, Eisdorder C and Fann WE, eds. Springer Publ. Co., New York, pp. 137-145, 1982.
114. Dunner DL: Intrinsic pharmacology of mental illness: affective disorders, in Hippus H and Winokur G, eds. Clinical Psychopharmacology, Excerpta Medica; Amsterdam, Holland, 1983, pp. 13-27.
115. Avery DH, Wilson LG, and Dunner DL: "Diagnostic subtypes of depression as predictors of therapeutic response," in Treatment of depression: old controversies and new approaches, PJ Clayton and JE Barrett (eds.), Raven Press, New York, pp. 193-205, 1983.
116. Dunner DL: Subtypes of bipolar affective disorder with particular regard to bipolar II. Psychiatric Developments 1: 75-86, 1983.

117. Dunner DL: "Drug treatment of the acute manic episode" in Psychiatry Update: The American Psychiatric Association Review, Vol. II, Grinspoon L (ed.), American Psychiatric Press, Inc., Washington D.C., pp. 293-302, 1983.
118. Dunner DL: "Recent genetic studies of bipolar and unipolar depression" in The Affective Disorders, Davis JM and Maas JW (eds), American Psychiatric Press, Inc., Washington, D.C., pp. 183-192, 1983.
119. Dunner DL and Dunner PZ: Psychiatry in China: Some personal observations. Biol. Psychiat. 18:799-801, 1983.
120. Reichler BD, Clement JL, and Dunner DL: Chart review of alcohol problems in adolescent psychiatric patients in an emergency room. J. Clin. Psychiat. 44:330-339, 1983.
121. Rosen LN, Rosenthal NE, VanDusen PH, Dunner DL, and Fieve RR: Age at onset and number of psychotic symptoms in Bipolar I and schizoaffective disorder. Amer. J. Psychiat. 140:1523-1524, 1983.
122. Rosen LN, Rosenthal NE, Dunner DL, and Fieve RR: Social outcome compared in psychotic and non-psychotic bipolar I patients. J. Nerv. Ment. Dis. 171; 272-275, 1983.
123. Dunner DL: "Relationship of Anxiety Disorders to Affective Disorders," Neuropsychiatric Research, E Usdin, M Goldstein, AJ Friedhoff, A Georgotas (eds), pp. 267-274, 1983.
124. Dunner DL: "Affective Disorders" in Current Emergency Therapy, 84, Edlich RF and Spyker DA, eds. Appleton-Century-Crofts, Norwalk, CT, pp. 349-352, 1984.

125. Dunner DL, Shen QJ, Zheng YP, and Dunner PZ: A study of primary affective disorders in the People's Republic of China. Biol. Psychiat. 19:353-359, 1984.
126. Myers K and Dunner DL: Acute viral encephalitis complicating a first manic episode. J. Fam. Practice 18:403-407, 1984.
127. Fieve RR, GO R, Dunner DL, and Elston R: Search for biological/genetic markers in a long-term epidemiological and morbid risk study of affective disorders. J. Psychiat. Res. 18:425-445, 1984.
128. Myers KM and Dunner DL: Self and other directed violence on a closed acute-care ward. Psychiatric Quart. 56:178-188, 1984.
129. Dunner DL: "Affective Disorders" in Current Emergency Therapy, 85, Edlich RF and Spyker DA, eds., Aspen Systems Corp., Rockville, MD, pp. 395-398, 1985.
130. Avery DH, Osgood TB, Ishiki DM, Wilson LG, Kenny M, and Dunner DL: The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorder. Amer. J. Psychiat. 142:844-848, 1985.
131. Dunner DL: "Affective Disorder: Clinical Features" in Psychiatry, Michels R, Cavenar JO Jr., Brodie HKH, Cooper AM, Buze SB, Judd LJ, Klerman GL, and Solnit AI, eds. JB Lippincot Co., Philadelphia, PA Vol I, Ch. 59, pp. 1-13, 1985.
132. Dunner DL: Anxiety and panic: relationship to depression and cardiac disorders. Psychosomatics (Suppl.) 26:18-21, 1985.

133. Sylvester C, Reichler RJ, Hyde TS, and Dunner DL: "Children at risk for panic and anxiety disorder: a preliminary report." In Biological Psychiatry: Clinical and pharmacological studies in psychiatric disorders. Burrows GD, Norman TR, and Dennerstein L: eds. John Libbey, London and Paris, 1985, pp. 115-120.
134. Loebel AD, Hyde TS, Dunner DL: Early placebo response in anxious and depressed patients. J. Clin. Psychiatry, 47:230-233, 1986.
135. Dager SR, Comess KA, and Dunner DL: Differentiation of anxious patients by two-dimensional echocardiographic evaluation of the mitral valve. Amer. J. Psychiatry 143:533-535, 1986.
136. Cowley DS, Dager SR, and Dunner DL: Lactate induced panic in primary affective disorder. Amer. J. Psychiatry 142:646-648, 1986.
137. Khan A, Lee E, Dager S, Hyde T, Raisys V, Avery D, and Dunner D: Platelet MAO-B activity in anxiety and depression. Biol. Psychiatry 21:847-849, 1986.
138. Dunner DL, Ishiki D, Avery DH, Wilson LG, and Hyde TS: Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: A controlled study. J. Clin. Psychiatry 47:458-460, 1986.
139. Dager SR, Comess KA, Saal AK, and Dunner DL: Mitral valve prolapse in a psychiatric setting: diagnostic assessment, research, and clinical implications. Integrative Psychiatry 4:211-223, 1986.
140. Dunner DL: Stability of bipolar II affective disorder as a diagnostic entity. Psychiatric Annals 17:18-20, 1987.

141. Dager SR, Cowley DS, Dunner DL: Biological markers in panic states; lactate induced panic and mitral valve prolapse. Biol. Psychiatry 22:339-359, 1987.
142. Dager SR, Khan A, Comess KA, Raisys V, and Dunner DL: Mitral valve abnormalities and catecholamine activity in anxious patients. Psychiatry Res. 20:13-18, 1987.
143. Cowley DS, Dager SR, Foster SI, and Dunner DL: Clinical characteristics and response to sodium lactate of patients with infrequent panic attacks. Amer. J. Psychiat. 144:795-798, 1987.
144. Dunner DL, Myers J, Khan A, Avery D, Ishiki D, and Pyke R: Adinazolam, a new antidepressant: Findings of a placebo-controlled, double-blind study in outpatients with major depression. J. Clin Psychopharm. 7:170-172, 1987.
145. Cowley DS, Hyde TS, Dager SR, and Dunner DL: Lactate infusions: the role of baseline anxiety. Psychiatry Res. 21:169-179, 1987.
146. Cohen S, Fligner CL, Raisys VA, Lutni R, and Dunner DL: A case of non-neuroleptic malignant syndrome. J. Clin. Psychiatry, 48:287-288, 1987.
147. Dager SR, Holland JP, Cowley DS, and Dunner DL: Panic disorder precipitated by exposure to organic solvents in the work place. Amer. J. Psychiat. 144:1056-1058, 1987.
148. Khan A, Cohen S, Stowell M, Capwell R, Avery D, and Dunner DL: Treatment options in severe psychotic depression. Convulsive Therapy, 3:93-99, 1987.

149. Dunner DL: High risk studies: the impact of research design on research results. Comp. Psychiatry, 28:363-368, 1987.
150. Meibach RC, Dunner DL, Wilson LG, Ishiki D, and Dager SR: Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial. J. Clin. Psychiatry, 48:355-358, 1987.
151. Dunner DL and Clayton PJ: "Drug treatment of bipolar disorder." In Psychopharmacology: The Third Generation of Progress, Meltzer HY, ed., New York, Raven Press, 1987, pp. 1077-1083.
152. Cowley DS, Dager SR, and Dunner DL: Lactate infusion in major depression without panic attacks. J. Psychiat Res., 21:243-248, 1987.
153. Cohen S, Khan A, Clark A, Goldner M, and Dunner DL: Hospitalization effect in acute mania. Gen. Hosp. Psychiatry, 10:1-4, 1988.
154. Dunner DL: "High risk studies: the impact of research design on research results." In Relatives at Risk for Mental Disorder, Dunner DL, Gershon ES, and Barrett JE, eds, New York, Raven Press, pp. 65-71, 1988.
155. Dunner DL: "The phenomenology of mania." In Perspectives in Psychopharmacology, Barchas JD and Bunney WE Jr., eds, Alan R. Liss, Inc., New York, pp. 475-482, 1988.
156. Dager SR, Saal AK, Commes DA, and Dunner DL: Mitral valve prolapse and the anxiety disorders, Hosp. and Comm. Psych, 39:517-527, 1988.

157. Cowley DS, Dager SR, McClellan J, Roy-Byrne PP, and Dunner DL: Response to lactate infusion in generalized anxiety disorder, Biol Psychiatry, 24:409-414, 1988.
158. Khan A, Johnsen F, Avery DH, Cohen S, Scherzo B, and Dunner DL: DST results in non-psychotic depressed outpatients, Amer. J. Psychiat. 145:1153-1156, 1988.
159. Dunner DL: "Mania" in Handbook of Clinical Psychopharmacology, Trupin JP, Shader RI, and Harnett DS, eds., Jansen Aronsen Inc., Northvale, NJ, pp. 97-109, 1988.
160. Cowley DS and Dunner DL: Response to sodium lactate in panic disorder: relationship to presenting clinical variables, Psychiatry Research, 25:253-259, 1988.
161. Dager SR, Roy-Byrne PP, and Dunner DL: "Stress, anxiety and the cardiovascular system," in Handbook of Anxiety (Vol. 2), Noyes R, Roth M, and Burrows GD, eds., Elsevier, pp. 399-429, 1988.
162. Dager SR, Holland JP, Cowley DS, and Dunner DL: Panic attacks and exposure to chemical agents (letter). Amer. J. Psychiat. 145:532-533, 1988.
163. Dunner DL: "Affective disorders," in Conn's Current Therapy, Rakel RE, ed., WB Saunders Co., Philadelphia, PA, pp. 994-1002, 1989.
164. Dager SR, Cowley DS, Dorsa DM, and Dunner DL: Plasma beta-endorphin response to lactate infusion, Biol. Psychiatry, 25:245-245, 1989.
165. Khan A, Cohen S, Dager S, Avery DH, and Dunner DL: Onset of response in relation to outcome in depressed outpatients with placebo and imipramine, J Affective Disorders, 17:33-38, 1989.

166. Cowley DS, Dager SR, and Dunner DL: Lactate response in patients with primary major depression (letter). Psychiatry Research, 27:357-358, 1989.
167. Roy-Byrne PP, Dager SR, Cowley DS, Vitaliano P, and Dunner DL: Relapse and rebound following discontinuation of benzodiazepine treatment of panic attacks: Alprazolam versus diazepam. Amer. J. Psychiat. 146:860-865, 1989.
168. Dager SR, Comess KA, Saal AK, Sisk EJ, Beach KW, and Dunner DL: Diagnostic Reliability of M-Mode Echocardiography for Detecting Mitral Valve Prolapse in 50 Consecutive Panic Patients. Compr Psych, 30:369-375, 1989.
169. Cohen S and Dunner DL: Bipolar affective disorder: Review and update. In Modern Perspectives in the Psychiatry of the Affective Disorders. Howells JG, ed. Brunner/Mazel, New York, 1989, pp262-274.
170. Amsterdam JD, Dunner DL, Fabre LF, Rush AJ, and Goodman LI: Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression. Pharmacopsychiatry 22:137-143, 1989.
171. Dager SR and Dunner DL: "Anxiety and mitral valve prolapse" in Anxiety and the Heart Rosenman R and Byrne D (Eds), Hemisphere, New York, pp. 277-293, 1989.
172. Dunner DL: "Affective disorders" in Conn's Current Therapy 1990, R.E. Raykel ed., W.B. Saunders Co., Philadelphia, PA, pp. 1014-1022, 1990.

173. Dager SR, Khan A, Cowley D, Avery DH, Elder J, Roy-Byrne, and Dunner DL: Characteristics of placebo response during long-term treatment of panic disorder. Schizophrenia Bull 26:273-278, 1990.
174. Avery DH, Khan A, Dager SR, Cox GB, and Dunner DL: Bright light treatment of winter depression: Morning versus evening light. ACTA Psychiatrica Scand 82:335-338, 1990.
175. Avery DH, Khan A, Dager S, Cohen S, Cox G, and Dunner DL: Is morning bright light exposure superior to evening light in treating Seasonal Affective Disorder? Psychopharm Bull 26: 521-524, 1990.
176. Perry PJ, Garvey MJ, Dunner DL, Rush AJ, and Kyhl J: A report of trazodone-associated laboratory abnormalities. Therapeutic Drug Monitoring 12:517-519, 1990.
177. Colombo M, Cox G, and Dunner DL: Assortative mating in affective and anxiety disorders: Preliminary findings. Psychiatric Genetics 1:35-44, 1990.
178. Avery DH, Khan A, Dager SR, Cohen S, Cox GB, and Dunner DL: Morning or evening bright light treatment of winter depression? The significance of hypersomnia. Biol Psychiatry 29:117-126, 1991.
179. Cowley DS, and Dunner DL: "Benzodiazepines in anxiety and depression" in Benzodiazepines in Clinical Practice: Risks and Benefits. Roy-Byrne, PP and Cowley DS, Eds., American Psychiatric Press, Inc., Washington, D.C., pp 37-56, 1991.
180. Khan A, Dager SR, Cohen S, Avery DH, Scherzo B, and Dunner DL: Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology 4:125-130, 1991.

181. Ward N, Whitney C, Avery D, and Dunner DL: The analgesic effects of caffeine in headache. Pain 44:151-115, 1991.
182. Dunner DL: Depression: Challenges for the future. J Clin Psychiatry 52:5 (Suppl): 44-51, 1991.
183. Cowley DS, Dager SR, Roy-Byrne PP, Avery DH, and Dunner, DL: Lactate vulnerability after alprazolam versus placebo treatment of panic disorder. Biol Psychiatry 30:49-56, 1991.
184. Dunner DL: Differential diagnosis of bipolar disorder. J Clin Psychopharmacology 12: 75-125, 1992.
185. Dunner DL and Dunbar GC: Optimal dose regimen for paroxetine. J Clin Psychiatry 53: 2 (Suppl) 21-26, 1992.
186. Dunner DL, Cohn JB, Walshe T III, Cohn CK, Feighner JP, Fieve RR, Halikas JP, Hearst ED, Settle EC Jr, Menolascino FJ, Muller DJ: Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 53:2 (Suppl) 57-60, 1992.
187. Roy-Byrne PP, Vitaliano PP, Cowley DS, Luciano G, Zheng YP, and Dunner DL: Coping in panic and major depressive disorder: Relative effects of symptom severity and diagnostic comorbidity. J Nerv Ment Dis 180: 179-183, 1992.
188. Shores MM, Glubin T, Cowley DS, Dager SR, Roy-Byrne PP, and Dunner DL: The relationship between anxiety and depression: A clinical comparison of generalized anxiety

- disorder, dysthymic disorder, panic disorder, and major depressive disorder. Compr Psychiatry 33:237-244, 1992.
189. Tay LK and Dunner DL: A report on three patients with "rapid cycling" unipolar depression. Compr Psychiatry 33:253-255, 1992.
190. Dager SR, Loebel JP, Claypool K, Case M, Budech CB, and Dunner DL: Oxiracetam in the treatment of primary dementia of the Alzheimer's type: A small case series. Int J Geriatric Psychiatry 7:905-912, 1992.
191. Dunner DL: Diagnostic and treatment considerations in the depressed elderly patient. Advances in Therapy 9:350-359, 1992.
192. Dager SR, Roy-Byrne P, Hendrickson H, Cowley DS, Avery DH, Hall KC and Dunner DL: Long-term outcome of panic states during double-blind treatment and after withdrawal of alprazolam and placebo. Annals of Clin Psychiatry 4: 251-258, 1992.
193. Dunner DL: ""Diagnostic and treatment considerations for the depressed elderly patient" in Serotonin: Reshaping the treatment of depression. Medicine Publishing Foundation, Symposium Series 32. Toronto, The Medicine Group (Canada) LTD, pp. 43-52, 1992.
194. Avery DH, Bolte MA, Dager SR, Wilson LG, Weyer M, Cox GB and Dunner DL: Dawn simulation treatment of winter depression: A controlled study. Amer J Psychiatry 150:113-117, 1993.
195. Dunner DL: Diagnosing and treating bipolar II disorder. Directions in Psychiatry 13:1-8, 1993.

196. Flick SM, Roy-Byrne PP, Cowley DS, Shores MM and Dunner DL: DSM-III-R personality disorders in a mood and anxiety disorders clinic: Prevalence, comorbidity, and clinical correlates. J Affective Disorders 27:71-79, 1993.
197. Dunner DL: A review of the diagnostic status of "Bipolar II" for the DSM-IV work group on mood disorders. Depression 1:2-10, 1993.
198. Bauer MS and Dunner DL: Validity of seasonal pattern as a modifier for recurrent mood disorders for DSM-IV. Compr Psychiatry 34:159-170, 1993.
199. Wingerson D, Sullivan M, Dager S, Flick S, Dunner D, and Roy-Byrne P: Personality traits and early discontinuation from clinical trials in anxious patients. J Clin Psychopharmacology 13:194-197, 1993.
200. Dunner DL: Diagnostic Assessment. Psychiatric Clinics of North America 16: 431-441, 1993.
201. Nelsen MR and Dunner DL: Treatment resistance in unipolar depression and other disorders. Psychiatric Clinics of North America. 16:541-566, 1993.
202. Wu LH and Dunner DL: Suicide attempts in rapid cycling bipolar patients. J Affective Disorders 29:57-61, 1993.
203. Dunner DL and Tay LK: Diagnostic reliability of the history of hypomania in bipolar II patients and patients with major depression. Compr Psychiatry 34:303-307, 1993.
204. Dunner DL: Managing the patient with depression and anxiety. Eur Psychiatry 8 (Suppl): 95-125, 1993.

205. Bauer MS, Calabrese J, Dunner DL, Post R, Whybrow PC, Gyulai L, Tay LK, Younkin SR, Bynum D, Lavori P, and Price RA: Multisite data reanalysis of the validity of rapid cycling as a course modifier for bipolar disorder in DSM-IV. Amer J Psychiatry 151:506-515, 1994.
206. Dunner DL: An overview of paroxetine in the elderly. Gerontology 40 (Suppl):21-27, 1994.
207. Dunner DL: Commentary on "Placebo as a treatment for depression." Neuropsychopharmacology10:273-274, 1994.
208. Heiligenstein JH, Faries DE, Rush AJ, Andersen JS, Pande AC, Roffwarg HP, Dunner DL, Gillin JC, Lahmeyer H, Zajecka J, Tollefson GD and Gardner DM: Response patterns in depressed outpatients with and without melancholia: A double blind placebo-controlled trial of fluoxetine versus placebo. J Affective Disorders 30:163-173, 1994.
209. Heiligenstein JH, Faries DE, Rush AJ, Andersen JS, Pande AC, Roffwarg HP, Dunner D, Gillin JC, James JP, Lahmeyer H, Zajecka J, Tollefson GD, and Gardner DM: Latency to rapid eye movement sleep as a predictor of treatment response to fluoxetine and placebo in non-psychotic depressed outpatients. Psychiatry Research, 52:327-339, 1994.
210. Dunner DL and Benjamin GAH: Bipolar affective disorder (manic depressive illness). The Bar Examiner 63:25-32, 1994.
211. Dunner DL: Therapeutic considerations in treating depression in the elderly. J Clin Psychiatry 55 (Suppl):48-58, 1994.
212. Shrivastava RK, Cohn C, Crowder J, Davidson J, Dunner D, Feighner J, Kieve A, and Patrick R: Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clinical Psychopharm: Vol. 14, No. 5, 1994.

213. Dunner DL: Pharmacological treatment of mood disorders. Current Opinion in Psychiatry 8:7-12, 1995.
214. King MK, Schmaling KB, Cowley DS and Dunner DL: Suicide attempt history in depressed patients with and without a history of panic attacks. Compr Psychiatry 36:25-30, 1995.
- +++++215. Cowley DS, Dager SR, Dunner DL: "The lactate infusion challenge" in Asnis GM, VanPraag HM, Eds. Panic Disorder: Clinical Biological and Treatment Aspects. John Wiley & Sons, New York, pp. 206-232,-232, 1995.
216. Nelsen MR, Dunner DL. Clinical and differential diagnostic aspects of treatment resistant depression. J Psych Research 29:43-50, 1995.
217. Han L, Schmaling KB, Dunner DL. Descriptive validity and stability of diagnostic criteria for dysthymic disorder. Compr Psychiatry 36:338-343, 1995.
218. Montgomery SA, Dunner DL, Dunbar GC. Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 5:5-13, 1995.
219. Tsuang D, Cowley D, Ries R, Dunner DL, and Roy-Byrne PP: The effects of substance use disorder on the clinical presentation of anxiety and depression in an outpatient psychiatric clinic. J Clin Psychiatry 56:549-555, 1995.
220. Dunner, DL "Comment and review" in PJ Goodnick, Ed. Predictors of treatment response in mood disorders. American Psychiatric Press, Inc. Washington, DC pp. 199-213, 1995.

221. Dunner DL "Bipolar depression with hypomania (Bipolar II)" in Widiger TA, Frances AJ, Pincus HA, Ross R, First MB, and Davis, WW, eds. DSM-IV Sourcebook Volume 2, Washington, DC, American Psychiatric Association, pp 53-63, 1996.
222. Bauer MS, Dunner DL "Validity of seasonal pattern as a modifier for recurrent mood disorders in DSM-IV" in Widiger TA, Frances AJ, Pincus HA, Ross R, First MB, and Davis WW, eds. DSM-IV Sourcebook Volume 2, Washington, DC, American Psychiatric Association, pp 281-298, 1996.
223. Feinman JA and Dunner DL The effect of alcohol and substance abuse on the course of bipolar affective disorder. J Affective Disorders 37:43-49, 1996.
224. Dunner DL. "Efficacy of selective serotonin re-uptake inhibitors in the treatment of dysthymia" in Feighner JP and Boyer WF, Eds. Selective Serotonin Re-Uptake Inhibitors: Advances in Basic Research and Clinical Practice Second Edition, John Wiley & Sons, Chichester, pp 223-232, 1996.
225. Chien AJ and Dunner DL. The Tridimensional Personality Questionnaire in depression: State versus trait issues. J Psychiatric Res 30:21-27, 1996.
226. Dunner DL. Montgomery SA: Selective serotonin reuptake inhibitors: Therapeutic alternatives to the tricyclics in the treatment of major depression. Depression 5: 215-224, 1996.
227. Dunner DL, Schmalting KB, Hendrickson H, Becker J, Lehman A, Bea C: Cognitive therapy versus fluoxetine in the treatment of dysthymic disorder. Depression 4:34-41, 1996.

228. Dunner DL. Classification and assessment of mood and anxiety disorders. Current Review of Mood and Anxiety Disorders 1:1-11, 1996. ++
229. Dunner DL. Improving the quality of care of depressed patients with co-morbid psychiatric disorder: A review. Clinical Performance and Quality Healthcare 5:11-15, 1997.
230. Pages KP, Dunner DL. "Focus on dysthymic disorder and chronic depression" in DL Dunner and JF Rosenbaum, eds. The Psychiatric Clinics of North America Annual of Drug Therapy 1997. W. B. Saunders Co., Philadelphia, PA, pp 91-109, 1997.
231. Lott VM and Dunner DL: Depression and AXIS II disorders: Comorbidity and relationship to cooperativeness. Depression and Anxiety 4: 268-272, 1996/1997.
232. Dunner DL. Hendrickson HE, Bea C, Budech CB. Venlafaxine in dysthymic disorder. J Clin Psychiatry 58:528-531, 1997.
233. Dunner DL. "Diagnostic revisions for DSM-IV" in Goodnick, PJ Mania: Clinical and Research Perspectives, American Psychiatric Press, Inc. Washington DC, pp 3-10, 1998.
234. Dunner DL. "Mood Disorders" in RE Raykel Ed. Conn's Current Therapy, W.B. Saunders, Philadelphia, PA, pp 1141-1148, 1998.
235. Dunner DL. The issue of comorbidity in the treatment of panic. Int Clin Psychopharmacol 13 (suppl 4): S19-S24, 1998.
236. Dunner DL. Bipolar disorders in DSM-IV: Impact of inclusion of rapid cycling as a course modifier. Neuropsychopharmacology 19:189-193, 1998.

237. Dunner DL. Lithium carbonate: Maintenance studies and consequences of withdrawal. J Clin Psychiatry59 (Suppl 6):48-55, 1998.
238. Dunner DL. An evaluation of pharmaceutical agents after their release for prescriptive use. Primary Psychiatry5:42-44,1998.
239. Dunner DL. Kumar R. Paroxetine: a review of clinical experience. Pharmacopsychiat 31:89-101, 1998.
240. Dunner DL. Zisook S, Billow AA, Batey, SR, Johnston JA, Ascher JA. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 59:366-373, 1998.
241. Dunner DL. Treatment of dysthymic disorder. Depression and Anxiety 8, Suppl 1:54-58, 1998.
242. Fava M, Amsterdam JD, Deltito JA, Salzman C. Schwaller M, Dunner DL. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Annals of Clin Psychiatry10: 145-150, 1998.
243. Dunner DL. "Rapid-cycling bipolar affective disorder" in JF Goldberg and M Harrow eds Bipolar Disorders Clinical Course and Outcome, Washington DC, American Psychiatric Press, Inc, pp. 199-217, 1999.
244. Dunner DL. Long-term use of sedative and hypnotic medication. Arch Gen Psychiatry 56:335, 1999 (Commentary)

245. Avery DH, Claypoole K, Robinson L, Neumaier J, Dunner DL, Scheele L, Wilson L, Roy-Byrne P. Repetitive transcranial magnetic stimulation in treatment of medication-resistant depression. Preliminary data. J Nerv Ment Dis 187:114-117, 1999.
246. Dunner DL. "A two-illness model of bipolar disorder" by RT Jaffe, LT Young, and GM MacQueen: a commentary. Bipolar Disorders 1:3637, 1999.
247. Dunner DL, Hendrickson HE, Bea C, Budech CB, O'Connor E. Dysthymic disorder: Treatment with mirtazapine. Depression and Anxiety 10:68-72, 1999
248. Comtois KA, Cowley DS, Dunner DL, Roy-Byrne PP. Relationship between borderline personality disorder and axis I diagnosis in severity of depression. J. Clin Psychiatry 60:752-758, 1999.
249. Dunner DL. Duration of euthymia in dysthymic patients. Amer J Psychiatry 156:1992-1993, 1999.
250. Dunner DL, Neumaier JF. "Lithium use in clinical practice" in EE Bittar and N Bittar, eds. Biological Psychiatry, JAI press, Stamford CT, pp 569-583, 2000.
251. Neumaier JF, Dunner DL. "Toward a pathophysiology of bipolar disorder" in JC Soares, S Gershon eds. Bipolar Disorders: Basic Mechanisms and Therapeutic Implications, Marcel Dekker Inc. New York NY, pp 545-554, 2000.
252. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. NEJM 342:1462-1470, 2000.

253. Dunner DL. Optimizing lithium treatment. J Clin Psychiatry 61, Suppl 9:76-81, 2000.
254. Hyun M, Friedman SD, Dunner DL. Relationship of childhood physical and sexual abuse to adult bipolar disorder. Bipolar Disord 2:131-135, 2000.
255. Den Boer JA, Dunner DL. Physician attitudes concerning diagnosis and treatment of social anxiety disorder in Europe and North America. Int. J Psychiatry Clin Practice 3:513-519, 1999.
256. Yang T, Dunner DL. Differential Subtyping of Depression. Depression and Anxiety 13:11-17, 2001.
257. Dunner DK. Management of anxiety disorders: The added challenge of comorbidity. Depression and Anxiety 13:57-71, 2001.
258. Dunner, DL. Acute and maintenance treatment of chronic depression. J Clin Psychiatry 62 (Suppl 6): 10-16, 2001.
259. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Crits-Christoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl, Halbreich V. Effectiveness of St. John's Wort in major depression: A randomized controlled trial. JAMA 285: 1978-1986, 2001.
260. Fava, M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J, Cohen M: Efficacy and Safety of Mirtazapine in Major Depressive Disorder Patients After SSRI Treatment Failure. J Clin Psychiatry 62:413-420, 2001.

261. Dunner, DL, Kwong WJ, Houser TL, Richard, NE, Donahue RMJ, Khan, ZM. Improved health-related quality of life and reduced productivity loss after treatment with bupropion sustained release: a study in patients with major depression. Primary Care Companion J Clin Psychiatry 3:1,10-16, Feb 2001.
262. Hirschfeld RMA, Dunner DL, Keitner G, Klein DN, Koran LM, Kornstein SG, Markowitz JC, Miller I, Nemeroff CB, Ninan PT, Rush AJ, Schatzberg AF, Thase ME, Trivedi MH, Borian FE, Crits-Christoph P, Keller MB. Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. Biol. Psychiatry 51:123-133, 2002.
263. Dunner DL, Laird LK. Comparative safety and tolerability of nefazodone. J. Clin Psychiatry 63: (Suppl 1): 33-36, 2002.
264. Dunner DL, Hendrickson, HE, Bea C, Budech CB, Friedman SD. Dysthymic disorder: Treatment with citalopram. Depression and Anxiety 15:18-22, 2002
265. Dunner, DL, Toward an Expansion of Bipolar Disorders in DSM-V in Maj M, Akiskal HS, Lopez-Ibor JJ, Sartorius M Eds, Bipolar Disorder. WPA Series Evidence and Experience in Psychiatry. Vol. 5. John Wiley and Sons, Chichester, UK, pp. 55-57, 2002.
266. Thase, ML, Rush J, Manber, R., Kornstein, SG, Klein, DN, Markowitz, JC, Ninan, PT, Friedman, ES, Dunner, DL, Schatzberg, AF, Borian, FE, Trivedi, MH, Keller, MB, Differential Effects of Nefazodone and Cognitive Behavioral Analysis System of Psychotherapy on Insomnia Associated With Chronic Forms of Major Depression. J Clin Psychiatry 63:493-500, June 2002.

267. Zajecka J, Dunner DL, Gelenberg AJ, Hirschfeld RMA, Kornstein SG, Ninan PT, Rush AJ, Thase ME, Trivedi, MH, Arnow BA, Borian FE, Manber R, Keller MB. Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination, *J Clin Psychiatry* 63:8, 709-716, 2002.
268. Dunner DL. "Mania" in Smelser NJ and Baltes PB, eds.. 2001 International Encyclopedia of the Social & Behavioral Sciences, Pergamon, Oxford. Pp 9178- 9183, 2001.
269. Avery DH, Eder DN, Bolte MA, Helleksen CJ, Dunner DL, Vitiello MV, Prinz PN, Dawn simulation and bright light in the treatment of SAD: a controlled study. *Biol. Psychiatry* 50: 205-216, 2001.
270. Sanger TM, Tohen M, Vieta E, Dunner DL, Bowden CL, Calabrese JR, Feldman PD, Jacobs TG, Breier A. Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling. *J Affect Disorder* 73:155-161, 2003
271. Dunner DL. Current therapeutic approaches for dysthymic disorder. *Expert Rev. Neurotherapeutics* 3:119-125, 2003.
272. Manber R, Rush A, Thase ME, Arnow B, Klein D, Trivedi MH, Kornstein SG, Markowitz JC, Dunner DL, Munsaka M, Borian FE, Keller M: The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression. *Sleep*, 2003; 15:130-138.
273. Dunner DL. Drug interactions of lithium and other antimanic/mood-stabilizing medications. *J Clin Psychiatry* 64: supp 5, 38-43,2003.

274. Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD. Efficacy of controlled-release paroxetine in the treatment of late-life depression. *J Clin Psychiatry* 64:1065-1074, 2003.
275. Dunner DL, Goldstein DJ, Mallinrodt C, Lu Y, Detke MJ. Duloxetine in treatment of anxiety symptoms associated with depression. *Depress & Anxiety* 18; 53-61, 2003.
276. Gelenberg AJ, Trivedi MH, Rush AJ, Thara MG, Howland R, Klein DN, Kornstein SG, Dunner DL, Markowitz JC, Hirschfeld RMA, Keitner GI, Zajecka J, Kocsis JH, Russell JM, Miller I, Manber R, Arnau B, Rothbaum B, Munsaka M, Banks P, Borian FE, Keller MB. Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. *Biol Psychiatry* 54:8056-817, 2003.
277. Dunner DL., Anxiety and depression in the elderly: Implications for diagnosis and treatment, *CNS Spectrums* 8: 5, 2003.
278. Dunner DL., Treatment considerations for depression in the elderly. *CNS Spectrums*, 8:14-19, 2003.
279. Nemeroff CB, Heim CM, Thase ME, Klein DN, Rush AJ, Schatzberg AF, Ninan PT, McCullough JP, Jr., Weiss PM, Dunner DL, Rothbaum BO, Kornstein S, Keitner G, Keller MB. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. *Proc Natl Acad Sci USA* 100:14293-14296, 2003.
280. Dunner DL. Clinical consequences of under-recognized bipolar spectrum disorder. *Bipolar Disorders* 5:456-463, 2003.

281. Dunner DL. Multiple perspectives on bipolar disorder. *CNS Spectrums* 8:890, 2003.
282. Vo D, Dunner DL. Treatment resistant bipolar disorder: a comparison of rapid cyclers and non-rapid cyclers. *CNS Spectrums* 8:948-952, 2003.
283. Chun BJDH, Dunner DL. A review of antidepressant-induced hypomania in major depression: suggestions for DSM-V. *Bipolar Disorders*. 6:32-42, 2004.
284. Lyoo IK, Kim MJ, Stoll AL, Demopulos CM, Parow AM, Dager SR, Friedman SD, Dunner DL, Renshaw PF. Frontal Lobe matter density decreases in bipolar I disorder. *Biol Psychiatry* 55:648-651, 2004.
285. Dunner DL. Paroxetine controlled release: a viewpoint by David L. Dunner. *CNS Drugs* 18; 6:365-366, 2004.
286. Dager SR, Friedman SD, Parow A, Demopulous C, Stoll AL, Lyoo IK, Dunner DL, Renshaw PF. Brain metabolic alternations in medication-free patients with bipolar disorder. *Arch Gen Psychiatry* 61:450-458, 2004.
287. Kocsis JH, Rush AJ, Markowitz JC, Borian FE, Dunner DL, Koran CM, Klein DN, Trivedi MH, Arnow B, Keitner G, Kornstein SG, Keller MB. Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. *Psychopharm Bull*; 37:73-87, 2003.
288. Dunner DL. Correlates of suicidal behavior and lithium treatment in bipolar disorder. *J Clin Psychiatry* 65(Suppl 10): 5-10,2004.

289. Klein DN, Blalock JA, Kocsis JH, Markowitz JC, McCulough JP, Jr., Rush AJ, Trivedi MH, Borian FE, Arnow B, Dunner DL, Manber R, Rothbaum B, Thase ME, Keitner GI, Miler IW, Keller MB. Cognitive-Behavioral Analysis System of Psychotherapy as a maintenance treatment for chronic depression. *J Consult & Clin Psychology* 72:681-688, 2004.
290. Gelenberg AJ, Shelton RC, Crits-Christoph P, Keller MB, Dunner DL, Hirschfeld RMA, Thase ME, Russell JM, Lydiard RB, Gallop RJ, Todd L, Hellerstein DJ, Goodnick PJ, Keitner GI, Stahl SM, Halbreich U and Hopkins HS. The effectiveness of St. John's Wort in major depressive disorder: A naturalistic phase 2 follow-up in which nonresponders were provided alternate medication. *J Clin Psychiatry* 65:1114-1119, 2004.
291. Freidman SD, Dager SR, Parow A, Hirashima F, Demopulos C, Stoll AL, Lyoo IK, Dunner DL and Renshaw PF. Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. *Biol Psychiatry* 56:340-348, 2004.
292. Rush AJ, Trivedi MH, Carmody TJ, Ibrahim HM, Markowitz JC, Keith GI, Kornstein SG, Arnow B, Klein DN, Manber R, Dunner DL, Gelenberg AJ, Kocsis JH, Nemeroff CB, Fawcett J, Thase ME, Russell JM, Jody DN, Borian FE, Keller MB. Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. *Neuropsychopharmacology*. 30; 405-416, 2005.
293. Dunner DL. Treatment-resistant depression: an overview of the problem. *Prim Psychiatry* 12:27-29, 2005.
294. Dunner DL. Atypical antipsychotics: efficacy across bipolar disorder subpopulations. *J Clin Psychiatry* 66:20-26, supp 3, 2005.

295. Dunner DL. Double depression. *CNS Spectrums* 10:174, 2005.
296. Dunner DL. Hypomania. *Depression: Mind and Body* 1; 114-117, 2005.
297. Dunner DL. Dysthymia and double depression. *Int Rev Psychiatry* 17:3-8, 2005.
298. Dunner DL, D'Souza DN, Kajdasz DK, Detke MJ, Russell JM. Is treatment-associated hypomania rare with duloxetine: Secondary analysis of controlled trials in non-bipolar depression.. *J Affective Disorders* 87: 115-119, 2005.
299. Dunner DL. The role of pain in stress and anxiety. *Primary Psychiatry* 12:8-11, 2005.
300. Dunner DL. Safety and tolerability of emerging pharmacological treatments for bipolar disorder. *Bipolar disord.* 7; 307-325, 2005.
301. George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, Howland R, Kling MA, Moreno F, Rittberg B, Dunner DL, Schwartz T, Carpenter L, Burke M, Ninan P, Goodnick P. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. *Biol Psychiatry* 2005;58:364-73.
302. Avery DH, Holtzheimer III PE, Fawaz W, Russo J, Neumaier J, Dunner DL, Haynor DR, Claypoole KH, Wajdik C, Roy-Byrne P. A controlled study of repetitive transcranial magnetic stimulation in medication-resistant major depression. *Biol Psychiatry.* 2006; 59:187-194.
303. Dunner DL. Bipolar depression. *CNS Spectr.* 2005; 10:528.

304. Dunner DL. First episode: depression and panic disorder. *CNS Spectr.* 2005; 10:696-7.
305. Dunner DL .Depression, dementia or pseudodementia? *CNS Spectr.* 2005; 10:862
306. Dunner DL., Wohlreich MM, Mallinckrodt CH, Watkin JG, Fava M. Clinical consequences of initial duloxetine dosing strategies: comparison of 30 and 60 mg starting doses. *Curr Therapeutic Res* 2005; 66:522-540.
307. Dunner DL. "Lithium" in JK Aronson, *Side Effects of Drugs Annual* 28. Elsevier: Amsterdam: 2005, pp 23-27.
308. Dunner DL. First onset of schizophrenia. *CNS Spectr* 2006; 11:19.
309. Lyoo IK, Sung YH, Dager SR, Friedman SD, Lee JY, Kim SJ, Kim N, Dunner DL, Renshaw PF. Regional cerebral cortical thinning in bipolar disorder. *Bipolar Disord* 2006; 8:65-74.
310. Hwang J, Lyoo IK, Dager SR, Friedman SD, Oh JS, Lee JY, Kim SJ, Dunner DL, Renshaw PF. Basal ganglia shape alterations in bipolar disorder. *Am J Psychiatry* 2006; 163:276-285.
311. Dunner DL, Lipschitz A, Pitts CD, Davies JT; Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: Post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials. *Clin Ther* 2005; 27:1901-1911.
312. Dunner DL, Rush AJ, Russell JM, Burke M, Woodward S, Wingard P, Allen J. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. *J Clin Psychiatry* 2006; 67:688-695.

313. Dimidjian S, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis DC, Dunner DL, Jacobson NS. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. *J Consult Clin Psychol* 2006; 74:658-670.
314. Shelton RC, Haman KL, Rapaport MH, Kiev A, Smith WT, Hirschfeld RMA, Lydiard RB, Zajecka JM, Dunner DL. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. *J Clin Psychiatry* 2006; 67:1674-1681.
315. Dunner DL. Mirtazapine and nortriptyline similarly effective third-line treatments for depression. *Evid Based Ment Health* 2007; 10:16.
316. Michelson D, Adler LA, Amsterdam JD, Dunner DL, Nierenberg AA, Reimherr FW, Schatzberg AF, Kesley DK, Williams DW. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2007; 68:582-587.
317. Dunner DL. Venlafaxine in the treatment of unresolved symptoms of depression following antidepressant therapy. *Primary Psychiatry* 2007;14:39-49.
318. Avery DH, Holtzheimer PE 3<sup>rd</sup>, Fawaz W, Russo J, Neumaier J, Dunner DL, Haynor DR, Claypool KH, Wajdik C, Roy-Byrne P. Transcranial magnetic stimulation reduces pain in patients with major depression: a sham-controlled study. *J Nerv Ment Dis* 2007; 195:378-381.

319. Dunner DL. “Lithium” In JK Aronson, ed. Side Effects of Drugs Annual 29. Elsevier, Amsterdam, The Netherlands pp. 28-34, 2007.
320. Kim MJ, Lyoo IK, Dager SR, Friedman SD, Chey J, Hwang J, Lee YJ, Dunner DL, Renshaw PF. The occurrence of cavum septi pellucidum enlargement is increased in bipolar disorder patients. *Bipolar Disord* 2007; 9:274-280.
321. Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label study. *J Clin Psychiatry* 2007; 68: 1071-1077.
322. Bader CD, Dunner DL. Antidepressant-induced hypomania in treatment-resistant depression. *J. Psychiatric Practice* 2007;13:233-237.
323. Kocsis JH, Thase ME, Trivedi MH, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Dunner DL, Hirschfeld RMA, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen MS, Yan B, Ahmed S, Musgnung J, Ninan PT, Keller MB. Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT study. *J Clin Psychiatry* 2007; 68:1014-1023.
324. Keller MB, Trivedi MH, Thase ME, Shelton RC, Kornstein SG, Nemeroff CB, Friedman ES, Gelenberg AJ, Kocsis JH, Dunner DL, Hirschfeld RMA, Rothschild AJ, Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen RD, Yan B, Ahmed S, Musgnung J, Ninan PT. The prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: Outcomes from the 2-year and combined maintenance phases. *J Clin Psychiatry* 2007;68:1246-1256.

325. Bader CD, Dunner DL. Bipolar disorder not otherwise specified in relation to the bipolar spectrum. *Bipolar Disord* 2007;9:860-867.
326. Keller MB, Trivedi MH, Thase ME, Zajecka JM, Pedersen R, Yan B, Ahmed S, Schmidt M, Ninan PT. The prevention of recurrent episodes of depression with venlafaxine for two years (PREVENT) study: outcomes from the acute and continuation phases. *Biol Psychiat* 2007;62:1371-1379.
327. Whitmyer VG, Dunner DL, Kornstein SG, Meyers AL, Mallinckrodt CH, Wohlreich MM, Gonzales JS, Greist JH. A comparison of initial duloxetine dosing strategies in patients with major depressive disorder. *J Clin Psychiatry* 2007;68:1921-1930.
328. Bauer M, Beaulieu S, Dunner DL, Lafer B, Kpka R. Rapid cycling bipolar disorder-diagnostic concepts. *Bipolar Disorders* 2008 ;10 :153-162.
329. Lee JH, Dunner DL. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders. *Depression and Anxiety* 2008;25:91-97.
330. Ghaemi SN, Bauer M, Cassidy F, Malhi GS, Mitchell P, Phelps J, Vieta E, Youngstrom E for the ISBD Diagnostic Guidelines Task Force\*. Diagnostic guidelines for bipolar disorder: a summary of the International Society for Bipolar Disorders Diagnostic Guidelines Task Force Report. *Bipolar Disorders* 2008;10:117-128.
331. Dunner DL, Thase ME. Drs. Dunner and Thase reply. (Response to a letter to the editor). *J Clin Psychiatry* 2008;69:502-503.

332. Neumaier JF, Dunner DL. "Toward a pathophysiology of bipolar disorder" in Soares JC and Young AH, eds, *Bipolar Disorders, Basic Mechanisms and Therapeutic Implications*, 2<sup>nd</sup> Edition, Informa Healthcare, New York, 2007, pp. 545-553.
333. Dunner DL. "Major Depressive Disorder" in SH Fatemi and PJ Clayton, Eds. *The Medical Basis of Psychiatry*. 2008, Humana Press, Totowa, NJ. Pp 73-83.
334. Dobson KS, Hollon SD, Dimidjian S, Schmalzing KB, Kohlenberg RJ, Gallop RJ, Rizvi SL, Gollan JK, Dunner DL, Jacobson NS. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. *J Consult Clin Psychol* 2008;76:468-477.
335. Dunner DL, Wilson M, Fava M, Kornstein S, Munoz R, O'Reardon J, Trivedi M, Wohlreich M. Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder. *Depression and Anxiety* 2008;25: on line at: <http://www3.interscience.wiley.com>.
336. Dunner DL. Depression: issues related to predicting treatment response. *Primary Psychiatry* 2007;14:39-40.
337. Canuso, CM, Bossie CA, Zhu Y, Youssef E, Dunner DL. Psychotic symptoms in patients with acute mania. *J Affective Dis* 2008; 111: 164-169
338. Amsterdam JD, Williams D, Michelson D, Adler LA, Dunner DL, Nierenberg AA, Reimherr FW, Schatzberg AF. Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. *Neuropsychobiology* 2009;59:227-233.

339. Dunner DL. Effective treatments despite diagnostic complexity and diverse populations. Commentary regarding “Depressive disorders in the elderly: A review” by Chiu E, Ames D, Draper B and Snowden J. In H Herrman, M Maj and N Sartorius, eds. *Depressive Disorders, Third Edition*, Wiley-Blackwell, Chichester, West Sussex, UK 2009. pp 260-261.
340. Liebowitz MR, Salman E, Mech A, Dunner D, Johnson AE, Akhtar J, Pratap R. Ziprasidone monotherapy in bipolar II depression: an open trial. *J Affect Disord* 2009;118:205-208.
341. Rothschild AJ, Dunlop BW, Dunner DL, Friedman ES, Gelenberg A, Holland P, Kocsis JH, Kornstein SG, Shelton, R, Trevedi MH, Zajecka JM, Goldstein C, Thase ME, Pedersen R, Keller MB. Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. *Psychopharmacol Bull* 2009; 42: 5-20.
342. Kornstein SG, Dunner DL, Meyers AL, Whitmyer VG, Mallincrodt CH, Wohlreich MM, Detke MJ, Hollandbeck MS, Greist JH. A randomized, double-blind study of increasing or maintaining duloxetine dose in patients without remission of major depressive disorder after initial duloxetine therapy. *J Clin Psychiatry* 2008;69:1383-1392.
343. Brown E, Dunner DL, McElroy SL, Keck PE, Adams DH, Degenhardt E, Tohen M, Houston JP. Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression. *Int J neuropsychopharmacol* 2009; 12:773-782.
344. Reimherr F, Amsterdam J, Dunner D, Adler L, Zhang S, Williams D, Marchant B, Michelson D, Nierenberg A, Schatzberg A, Feldman P. Genetic polymorphisms in the treatment of depression: speculations from an augmentation study using atomoxetine. *Psychiatry Res* 2010; 30:67-73.

345. Lyoo IK, Dager SR, Kim JE, Yoon SJ, Friedman SD, Dunner DL, Renshaw PF. Lithium-induced gray matter volume increase as a neural component of treatment response in bipolar disorder: a longitudinal brain imaging study. *Neuropsychopharmacology* 2010;35:1742-1750.
346. Trivedi MH, Dunner DL, Kornstein SG, Thase ME, Zajecka JM, Rothschild AJ, Friedman ES, Shelton RC, Keller MB, Kocsis JH, Gelenberg A. Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. *J Affective Disord* 2010;126:420-429.
347. Carpenter LL, Janicak PG, Aaronson ST, Boyadjis T, Brock DG, Cook, IA, Dunner DL, Lanocha K, Solvason HB, Demitrack MA. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. *Depress Anxiety* 2012;29:587-596.
348. Dunner DL. Differentiation of various forms of depression. *Shanghai Arch Psychiatry* 2012; 24: 290-291.
349. Feldman RL, Dunner DL, Muller JS, Stone DA. Medicare patient experience with vagus nerve stimulation for treatment-resistant depression. *J Med Econ* 2012; September, epub.
350. Aaronson ST, Carpenter LL, Conway CR, Reimherr FW, Lisanby SH, Schwartz TL, Moreno FA, Dunner DL, Lesem MD, Thompson PM, Husain M, Vine CJ, Banov MD, Bernstein LP, Lehman RB, Brannon GE, Keepers GA, O'Reardon JP, Rudolph RL, Bunker M. Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: Acute and chronic effects. *Brain Stim* 2012;1:1-10.

351. Dunner DL. Anxiety Disorders: Anxiety. In The American College of Psychiatrists 50<sup>th</sup> Anniversary Past, Present and Future. JH Shore, Ed. 2013, The American College of Psychiatrists, Chicago, Il, pp 103-105.
352. Gelenberg AJ, Dunner DL, Rothschild AJ, Pedersen R, Dorries KM, Ninan PT. Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study. *J Nerv Ment Dis* 2013; 201:266-273.
353. Dunner DL, Laubmeier KK, Manos G, Forbes RA, Baker RA, Berman RM. Beneficial effects of adjunctive aripiprazole in major depressive disorder are not dependent on antidepressant therapy history: a post hoc analysis of 3 randomized, double-blind, placebo-controlled trials. *Prim Care Companion CNS Disord* 2012; 14: (E pub).
354. Dunner DL. Treatment-resistant depression. *Taiwanese J of Psychiatry* 2013; 27: 110-120.
355. Janicak PG, Dunner DL, Aaronson ST, Carpenter LL, Boyadijis TA, Brock DG, Cook IA, Lanocha K, Solvason HB, Bonneh-Garkay D, Demitrack MA. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice. *CNS Spectrums* 2013; 18:322-332.
356. Wajdik C, Claypoole KH, Fawaz W, Holtzheimer PE 3<sup>rd</sup>, Neumaier J, Dunner DL, Haynor DR, Roy-Byrne P, Avery DH. No change in neuropsychological functioning after receiving repetitive transcranial magnetic stimulation treatment for major depression. *J ECT* 2014 (epub).
357. Dunner DL. Being an editor of a psychiatric journal. *Acad Psychiatry* 2014; 38:493-494.

358. Dunner DL, Aaronson S, Sackeim HA, Janicak PG, Carpenter LL, Boyadjis T, Brock DG, Cook I, Lanocha K, Solvason HB, Demitrack MA. A multisite, naturalistic, observational study of transcranial magnetic stimulation (TMS) for patients with pharmacoresistant major depression: durability of benefit over a one-year follow-up. *J Clin Psychiatry* 2014; 75:1394-1401.
359. Dunner DL. Combining antidepressants. *Shanghai Archives of Psychiatry* 2014;26 363-364.

ARTICLES SUBMITTED FOR PUBLICATION AND IN PRESS OR IN PREPARATION

Philip, NS, Dunner DL, Dowd SM, Aaronson ST, Brock D, Carpenter, LL, Demitrack MA, Horav S, Janicak, PG, George MS. Can medication free, treatment-resistant depressed patients who initially respond to TMS be maintained off medications? A prospective, 12-month multisite randomized pilot study.

Dimidjian S et al Jacobson 3 (allegiance)

Dunner DL Et al. Economic impact...

BOOKS

1. Dunner DL, Gershon ES and Barrett JE (eds). Relatives at risk for mental disorder. Raven Press, New York, NY, 1988.
2. Dunner DL, ed. Current Psychiatric Therapy. W.B. Saunders, Philadelphia, PA, 1993.
3. Dunner DL: Guest Editor, Psychopharmacology I. The Psychiatric Clinics of North America, W.B. Saunders, Philadelphia, 1993.
4. Dunner DL, Guest Editor Psychopharmacology II. The Psychiatric Clinics of North America, W.B. Saunders, Philadelphia, PA, 1993.
5. Dunner DL, ed. Current Psychiatric Therapy II. W.B. Saunders, Philadelphia, PA, 1997.
6. Dunner DL, Rosenbaum JF, eds. The Psychiatric Clinics of North America Annual of Drug Therapy 1997. W. B. Saunders, Philadelphia, PA, 1997.
7. Dunner DL, Rosenbaum JF, eds. The Psychiatric Clinics of North America Annual of Drug Therapy 1998. W. B. Saunders, Philadelphia, PA, 1998.

8. Dunner DL, Rosenbaum JF, eds. The Psychiatric Clinics of North America Annual of Drug Therapy 1999. W.B. Saunders, Philadelphia, PA, 1999.
9. Dunner DL, Rosenbaum JF, eds. The Psychiatric Clinics of North America Annual of Drug Therapy 2000. W.B. Saunders, Philadelphia, PA. 2000.
9. Dunner DL, Rosenbaum JF, eds. The Psychiatric Clinics of North America Annual of Drug Therapy 2001. W.B Saunders, Philadelphia, PA
10. Rosenbaum JF, Dunner DL, eds. Drug Therapy: Predictors of Response. The Psychiatric Clinics of North America, vol 26: no.2, WB Saunders, Philadelphia PA, June 2003.
11. Section Editor, "Psychopharmacological Treatment." Schatzberg AF and Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, Third Edition. American Psychiatric Publishing, Washington, D.C., 2003.
12. Section Editor, "Psychopharmacological Treatment." Schatzberg AF and Nemeroff CB, eds. The American Psychiatric Publishing Textbook of Psychopharmacology, Fourth Edition. American Psychiatric Publishing, Washington, D.C., 2009.

#### OTHER EDITORIAL EFFORTS:

1. Guest Editor, Treatment Resistant Depression, Primary Psychiatry Vol 12, No 2: Feb 2005.
2. Columnist, Interactive Case Conference, CNS Spectrums. Double Depression 10; 174, 2005; Depression in the Elderly 10: 354, 2005; First Episode: Depression and Panic Disorder 10; 696-697, 2005. Depression, dementia or pseudo dementia? 10:862, 2005; first onset of schizophrenia; 19, 2006.

3. Blier P, Keller MB, Pollack MD, Thase Me, Zajecka JM, Dunner DL. Preventing recurrent depression: long-term treatment for major depressive disorder. *J Clin Psychiatry* 2007;68:e06.Review.

#### PRESENTATIONS AND ABSTRACTS

1. Dunner DL, Gershon ES, and Goodwin FK: Heritable factors in the severity of affective illness. Presented at the Annual Meeting, American Psychiatric Association, San Francisco May 1970. (Sc. Proc. Amer. Psychiat. Assn., 123:187-188, 1970)
2. Goodwin FK, Dunner DL, and Axelrod J: Rapid elevation of biogenic amine metabolites in human CSF following probenecid. Presented at the Fourth Annual Winter Conference on Brain Research Snow Mass-at-Aspen, Colorado, January 1971. (Abstracted by Brain Information Service)
3. Goodwin FK, Murphy DL, Dunner DL, and Bunney WE Jr.: Lithium response in unipolar vs bipolar depression. Presented at the Annual Meeting, American Psychiatric Association, Washington, D.C., May 1971. (Sc. Proc. Amer. Psychiat. Assn., 124:110-111, 1971)
4. Gershon ES, Dunner DL, Stuart L, and Goodwin FK: Assortative mating in the affective disorders; a preliminary report. Presented at the Annual Meeting, American Psychiatric Association, Washington DC, May 1971, (Sci. Proc. Amer. Psychiat. Assn., 124: 209-210, 1971)
5. Goodwin FK, Post RM, Dunner DL, and Bunney WE Jr.: CNS amines and affective illness. Probenecid studies. Presented at the Annual Meeting, American Psychiatric Association, Dallas, Texas, May, 1972. (Sci. Proc. Amer. Psychiat. Assn., 125:47-48, 1972)

6. Fieve RR, Meltzer HL, Levitt M, and Dunner DL: Rubidium: Biochemical, behavioral and metabolic studies in humans. Presented at the Annual Meeting, American Psychiatric Association, Dallas, Texas, May 1972.
7. Bunney WE Jr., Dunner DL, Fieve RR, Katz MM, Mendlewicz J, Winokur G: Manic Depressive Illness. Council for Interdisciplinary Communication in Medicine, Ltd. (Audio tape) 1972.
8. Dunner DL: The Treatment of Tomorrow's Depression. Panel Discussion at the 10th Western Divisional Meeting, American Psychiatric Association, San Diego, CA. October 1972, (Audio-Digest Foundation 1 No. 10) (Psychiatry-Audio tape.)
9. Dunner DL: Psychotropic Drugs in Clinical Practice. Presented at the 167th Annual Convention of the Medical Society of the State of New York, New York, NY, February 1973. (New York State J. of Med. 74:376-377, 1974.)
10. Dunner DL: Clinical Characteristics of Lithium Prophylaxis Failures. Presented at the 18th Annual Conference, VA Studies in Mental Health and Behavioral Sciences. New Orleans, LA, March 1973. (Highlights of the 18th Annual Conference, pp. 67-69, 1973).
11. Perel J, Levitt M, and Dunner DL: Plasma and cerebrospinal fluid probenecid concentrations as related to accumulation of acidic biogenic amine metabolites in man. Presented to FASEB, Atlantic City, NJ, April 1973. (Fed. Proc. 32:696, 1973.)
12. Dunner DL, Meltzer HL, and Fieve RR: CSF Rubidium metabolism in depression. Presented at the annual meeting, Amer. Psychiatric Assn., Honolulu, Hawaii, May 1973. (Sci. Proc. Amer. Psychiat. Assn.), 126:190-191, 1973.

13. Dunner DL: Lithium carbonate in the treatment of mood disorders. Presented to Brooklyn District Branch, Amer. Psych. Assoc., Brooklyn, NY, November 1973.
14. Dunner DL: Amine precursors in depression: Studies combining L-dopa and L-tryptophan. Presented at the 12th annual meeting, American College of Neuropsychopharmacology, Palm Springs, CA, December 1973. Abstracted in Psychopharmacology Bulletin, 10:56-57, 1974.
15. Dunner DL: Recent research on classification, genetics, and treatment of depression. Presented to the New York Society of Clinical Psychologist, Inc., New York, May 1974.
16. Dunner DL and Fieve RR: Affective disorders: studies with amine precursors. Presented at the annual meeting, Amer. Psychiat. Assoc., Detroit, Michigan, May 1974. (Sci. Proc. Amer. Psychiat. Assn.), 127:160, 1974).
17. Dunner DL: Treating affective states with lithium. Medical World News Review, Psychiatry Issue, 129-30, 1974.
18. Dunner DL, Fleiss JL, and Fieve RR: Lithium carbonate prophylaxis failure. Presented at the annual meeting, Amer. Psychiat. Assn., Anaheim, CA, May 1975. (Sci. Proc. Amer. Psychiat. Assn. 128:215-216, 1975)
19. Fieve RR, Dunner DL, Stallone F, Kumbaraci T, and Fleiss JL: Lithium prophylaxis of three depression sub-types. Presented at the annual meeting, American Psychiatric Assn., Anaheim, CA, May 1975. (Sci. Proc. Amer. Psychiatry. Assn. 128:216-217, 1975)
20. Farkas T, Dunner DL, and Fieve RR: L-tryptophan in depression. Presented at the 30th annual meeting, Society of Biological Psychiatry, New York, May 1975.

21. Diamond S, Rubenstein A, Dunner DL, and Fieve RR: Menstrual problems in women with primary affective illness. Presented at the 30th annual meeting, Society of Biological Psychiatry, New York, May 1975.
22. Dunner DL and Fieve RR: The lithium ion: its impact on diagnostic practice. Presented at "Biological Predictors in Psychiatric Disorders" (International symposium sponsored by the University of Tennessee Center for the Health Sciences), Memphis, Tennessee, December 1975.
23. Dunner DL, Patrick V, and Fieve RR: Rapid cycling manic depressive patients. Presented at the annual meeting, American Psychiatric Assn., Miami, Florida, May 1976. (Sci. Proc. Amer. Psychiat. Assn. 129:299-300, 1976)
24. Dunner DL: Affective illness and the family (Panel). Presented at the annual meeting, American Psychiatric Assn., Miami, Florida, May 1976. (Sci Proc Amer Psychiat Assn. 129:339-340, 1976)
25. Dempsey GM, Dunner DL, Meltzer HL, and Fieve RR: Lithium toxicity. Presented at the First International Symposium on Neurotoxicology, New York, May 1976)
26. Dunner DL, Levitt M, Kumbaraci T, and Fieve RR: Erythrocyte catechol-o-methyltransferase activity in primary affective disorder. Presented at the annual meeting, Society of Biological Psychiatry, San Francisco, CA, June 1976. (Abstracts, p. 60)
27. Dunner DL and Fieve RR: The effect of lithium in depressive sub-types. Presented at the 10th Congress, Collegium Internationale Neuropsychopharmacologicum, Quebec, Canada, July 1976. (Abstracts, p. 25)

28. Fieve RR, Meltzer HL, Kumbaraci TE, and Dunner DL: Multiple enzyme profiles as possible biochemical markers tests for affective disorders. Presented at the 10th Congress, Collegium Internationale Neuropsychopharmacologium, Quebec, Canada, July 1976. (Abstracts, p. 221)
29. Barkai A, Gross HA, Dunner DL, Fieve RR: Myoinositol and other sugars in cerebrospinal fluid from patients with affective disorder. Presented at the sixth annual meeting of the Society for Neuroscience, Toronto, Canada, November 1976 (Abstracts 11, p. 593).
30. Meltzer HL, Fieve RR, and Dunner DL: Lithium treatment regulates the activity of the lithium pump in manic depressive subjects. Presented at the annual meeting of the Psychiatric Research Society, Salt Lake City, Utah, February 1977.
31. Dunner DL, Patrick V, and Fieve RR: Life events and the onset of bipolar affective illness. Presented at the annual meeting, American Psychiatric Assn., Toronto, Canada, May 1977. (Sci. Proc. Amer. Psychiat. Assn. 130:105, 1977)
32. Dunner DL, Meltzer HL, and Fieve RR: Clinical correlates of the lithium pump. Presented at the annual meeting, American Psychiatric Assn., Toronto, Canada, May 1977. (Sci. Proc. Amer. Psychiat. Assn. 130:150, 1977)
33. Dunner DL, Meltzer HL, and Fieve RR: Erythrocyte lithium studies. Presented at the VI World Congress of Psychiatry, Honolulu, Hawaii, August 1977. (Abstracts, p.113)
34. Dunner DL, Igel G, and Fieve RR: Social adjustment in primary affective disorder. Presented at the VI World Congress of Psychiatry, Honolulu, Hawaii, August 1977 (Abstracts, p. 251).

35. Dunner DL, Igel G, and Fieve RR: Social adjustment in primary affective disorder. Presented at the annual meeting of the Psychiatric Research Society, Rochester, NY, November 1977.
36. Dunner DL: Criteria for establishing a biochemical factor as a "marker" with special reference to catechol-o-methyltransferase. Presented at the annual meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1977.
37. Meltzer HL, Kassir S, Dunner DL, and Fieve RR: Active efflux of lithium from erythrocytes. Presented at the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1977.
38. Fieve RR, Meltzer HL, and Dunner DL: Clinical correlates of active efflux of lithium from erythrocytes. Presented at the annual meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1977.
39. Dunner DL and Fieve RR: The implications of family history in depression. Presented at the annual meeting of the American Psychiatric Assn., Atlanta, Georgia, May 1978. (Proc. Amer. Psychiatry. Assn. 134:107, 1978)
40. Nurnberger JI, Roose SP, Dunner DL, and Fieve RR: Unipolar Mania: a distinct clinical entity? Presented at the annual meeting of the American Psychiatric Assn., Atlanta, GA, May 1978. (Sci. Proc. Amer. Psychiat. Assn., 131:179, 1978)
41. Dunner DL, Hensel BM, and Fieve RR: Bipolar illness: factors in drinking behavior. Presented as new research to the annual meeting of the American Psychiatric Assn., Atlanta, GA, May 1978 (New Research #33).

42. Dunner DL, Roose SP, and Bone SR: Complications of lithium treatment in older patients. Presented at the International Lithium Conference - Controversies and Unresolved Issues. New York, NY 1978.
43. Dunner DL, Meltzer HL, and Fieve RR: Clinical aspects of lithium efflux from erythrocytes. Presented at the Second World Congress of Biological Psychiatry, Barcelona, Spain, August 1978 (Abstracts, p.133).
44. Fieve RR, Meltzer HL, and Dunner DL: Clinical trials of lithium in depressed patients. Presented at the second World Congress of Biological Psychiatry, Barcelona, Spain, 1978 (Abstracts - addenda).
45. Fieve RR, Meltzer HL, and Dunner DL: Lithium pump repression index predicts of prophylactic response. Presented at the second World Congress of Biological Psychiatry, Barcelona, Spain, August 1978 (Abstracts - addenda).
46. Dunner DL and Fieve RR: Catecholamine metabolizing enzymes and primary affective disorder. Presented at the fourth International Catecholamine Symposium. Pacific Grove, California 1978 (Abstracts 541, p.139).
47. Colt E, Dunner DL, Stallone F, and Fieve RR: Body composition and primary affective disorder. Presented at the annual meeting, Psychiatric Research Society, San Francisco, California, September 1978.
48. Dunner DL, Murphy D, Stallone F, and Fieve RR: Episode frequency in lithium treated patients. Presented at the 17th annual meeting, American College of Neuropsychopharmacology, Maui, Hawaii, December 1978.

49. Kuyler PL, Rosenthal LN, Igel G, Dunner DL, and Fieve RR: Psychopathology among children of manic depressive patients. Presented at the 34th annual meeting, Society of Biological Psychiatry, Chicago, Illinois, May 1979 (Abstracts, p. 113).
50. Go R, Dunner DL, and Fieve RR: Comparison of autosomal dominant and x-linked dominant models to a set of 65 bipolar proband families. Presented at the annual meeting, Psychiatric Research Society, Madison, Wisconsin, September 1979.
51. Colt E, Dunner DL, and Fieve RR: A high incidence of affective disorder in runners. Presented at the annual meeting, Psychiatric Research Society, Madison, Wisconsin, September 1979.
52. Dunner DL, Gentry R, Scribner B, Doerr H, and Martin D: Double-blind assessment of hemodialysis in schizophrenia. Presented at the 18th annual meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1979.
53. Goodnick PJ, Evans HE, Dunner DL, and Fieve RR: CSF levels of amino acids in aging and depression. Presented at the annual meeting, American Psychiatric Assn., San Francisco, California, May 1980 (Abstracts, pp. 292-293).
54. Dunner DL: Phenomenology of Bipolar I affective illness. Presented at the annual meeting, American Psychiatric Assn., San Francisco, California, May 1980 (Abstracts, p. 100).
55. Fieve RR, Goodnick PJ, Meltzer HL, and Dunner DL: Pharmacokinetics of lithium as a function of duration of therapy. Presented at the 12th meeting of the CINP, Goteborg, Sweden, June 1980 (Abstracts, p.142).

56. Dunner DL, Go R, and Fieve RR: A family study of patients with bipolar II illness (bipolar depression with hypomania). Presented at the annual meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1980 (Abstracts, p.25).
57. Avery DH, Wilson LG, and Dunner DL: Diagnostic subtypes of depression as predictors of therapeutic response. Presented at the 71st annual meeting, American Psychopathological Assn., New York, NY 1981.
58. Dunner DL: High risk studies in affective disorders. Presented at the "Conference on Biological Markers in Psychiatry and Neurology," New Orleans, Louisiana, May 1981.
59. Fieve RR, Go R, and Dunner DL: A morbid risk family study of affective disorders. Presented at the New Research Section, American Psychiatric Assn., New Orleans, Louisiana, May 1981 (Abstracts, p. NR36).
60. Peselow EP, Dunner DL, Fieve RR, Deutsch SI, and Kaufman M: Prophylaxis of unipolar depression. Presented at the annual meeting, American Psychiatric Assoc., New Orleans, Louisiana, May 1981. (Syllabus and Scientific Proceedings, p.185).
61. Goodnick PJ, Meltzer HD, Fieve RR, and Dunner DL: Diagnostic differences in lithium kinetics. Presented at the annual meeting, American Psychiatric Assn., New Orleans, Louisiana, May 1981. (Syllabus and Scientific Proceedings, p. 255).
62. Dunner DL: Recent genetic studies of bipolar and unipolar depression. Presented at the Brook Lodge Symposium on Affective Disorders, Kalamazoo, Michigan, October 1981.

63. Dealy RS, Ishiki DM, Avery DH, Wilson LG, and Dunner DL: Secondary depression in anxiety disorders. Presented at the annual meeting, American College of Neuropsychopharmacology, Coronado, California, December 1981 (Abstract).
64. Fieve RR, Go R, and Dunner DL: A blind multi-center morbid risk family study of 579 affective disorder probands and their relatives. Presented at the annual meeting, Psychiatric Research Society, Park City, Utah, March 1982 (Abstract).
65. Dunner DL: Antidepressants and the elderly. Presented at the annual meeting, American Psychiatric Assoc., Toronto, Canada, May 1982 (Abstracts, p.32).
66. Peselow ED, Dunner DL, Fieve RR, and Deutsch SI: Prophylactic efficacy of tricyclic antidepressants. Presented at the annual meeting, American Psychiatric Assn., Toronto, Canada, May 1982 (Abstracts, p. 242).
67. Dunner DL, GO RCP, and Fieve RR: A family study of patients with bipolar II illness (Bipolar depression with hypomania). Presented at the 13th Congress of the Collegium Internationale Neuropsychopharmacologicum, Jerusalem, Israel, June 1982 (Abstracts, p. 183).
68. Fieve RR, GO R, and Dunner DL: A morbid risk family study of affective disorders, a multi-center study. Presented at the 13th Congress of the Collegium Internationale Neuropsychopharmacologicum, Jerusalem, Israel, June 1982 (Abstracts p. 221).
69. Peselow ED, Dunner DL, Fieve RR, and Deutsch SI: Prophylactic efficacy of tricyclic antidepressants. Presented at the 13th Congress of the Collegium Internationale Neuropsychopharmacologicum, Jerusalem, Israel, June 1982 (Abstracts, p. 575).

70. Dunner DL and Dunner PZ: Clinical studies of affective disorder in People's Republic of China. Presented at the Annual Meeting, Psychiatric Research Society, Galveston, TX, November 19-20, 1982.
71. Dunner DL and Dunner PZ: Clinical studies of affective disorder in the Peoples Republic of China. Presented at the annual meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1982. Poster (Abstracts, p.78).
72. Branconnier RJ, Cole JD, Oxenkrug GF, Ghazvinian S, Dessain EC, Spera KF, Kane JM, Cole K, Sarantatios S, Dunner DL, and Avery DH: Cardiovascular effect of imipramine and bupropion in aged depressed patients. Presented at the annual meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 1982. Poster (Abstracts, p. 85).
73. Dunner DL, Zheng Yanping, Shen Qi Jie, and Dunner PZ: Clinical studies of affective disorder in Peoples Republic of China. Presented at the 38th Annual Meeting, Society of Biological Psychiatry, New York, NY, April 27-May 1, 1983. (Abstracts, p.63)
74. Dunner DL: Drug treatment of the acute manic episode. Presented at the 136th Annual Meeting, American Psychiatric Assn., New York, NY, April 30-May 6, 1983, Abstracts pp.5-6. (Part IV of the Annual Review)
75. Fieve RR, Go RCP, Dunner DL, and Elston RC: New conclusions on X-linkage in manic depressive illness. Presented at the Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 12-16, 1983.

76. Fieve RR, Dunner DL, and Go RCP: Sib-pair linkage analysis in bipolar I illness. Presented at the 137th Annual Meeting, American Psychiatric Association, Los Angeles, CA, May 5-11, 1984 (Abstracts, p.284).
77. Dager S, Comess K, Avery D, Myers J, and Dunner D: Mitral valve disease in anxious patients. Presented at the 137th Annual Meeting, American Psychiatric Association, Los Angeles, CA, May 5-11, 1984 (New Research #107)
78. Reichler RJ, Sylvester CE, Hyde TS, and Dunner DL: Identifying children at risk for panic and anxiety disorders. Presented at the 14th Collegium Internationale Neuropsychopharmacologicum Congress, Florence, Italy, June 19-23, 1984 (Abstracts, p.46).
79. Dunner DL and Loebel AD: Early placebo effects in anxious and depressed outpatients. Presented at the 14th Collegium Internationale Neuropsychopharmacologicum Congress, Florence, Italy, June 19-23, 1984 (Abstracts, p.325).
80. Dunner DL, Avery DH, and Ishiki D: The effect of alprazolam on panic attacks in patients with anxiety disorder. Presented at the 14th Collegium Internationale Neuropsychopharmacologicum Congress, Florence, Italy, June 19-23, 1984 (Abstracts, p.546).
81. Fieve RR, Go RCP, Dunner DL, and Elston RC: Genetics of manic depressive illness: present status of the X-linkage hypothesis. Presented at the 14th Collegium Internationale Neuropsychopharmacologicum Congress, Florence, Italy, June 19-23, 1984 (Abstracts, p.795).

82. Reichler RJ, Sylvester CE, Hyde TS, and Dunner DL: Children at risk for panic and anxiety disorder. Presented at the Annual Meeting, American College of Neuropsychopharmacology, San Juan Puerto Rico, December 11-14, 1984, Poster.
83. Avery DH, Dunner DL, and Ishiki DM: Nocturnal temperature discomfort and night sweats in primary depression and insomnia. Sleep Research 13:33, 1984.
84. Dager S and Dunner DL: Mitral valve prolapse in anxious patients. Presented at the annual meeting, Psychiatric Research Society, Tampa, Florida, March 15-16, 1985.
85. Dunner DL, Dager S, Cowley D: Mitral valve prolapse, lactate infusion and panic disorder. Presented at the 3rd Annual Meeting, West Coast College of Biological Psychiatry, Stanford, California, April 12-13, 1985.
86. Fieve RR, Peselow ED, and Dunner DL: The long-term efficacy of tricyclic antidepressants. Presented at the 138th Annual Meeting, American Psychiatric Association, Dallas, Texas, May 18-24, 1985 (Abstracts p.192).
87. Dunner DL: Cardiovascular aspects of generalized anxiety disorder. Presented at the 138th Annual Meeting, American Psychiatric Association, Dallas, Texas, May 18-24, 1984.
88. Khan A, Lee E, Hyde T, Dager S, Avery D, and Dunner DL: Platelet monamine oxidase activity in depression and anxiety. Presented at the IV World Congress of Biological Psychiatry, September 8-13, 1985, Philadelphia, Pennsylvania (Abstracts p.90).
89. Cowley DS, Dager SR, and Dunner DL: Lactate-induced panic in primary depression. Presented at IV World Congress of Biological Psychiatry, September 8-13, 1985, Philadelphia, PA. (Abstracts p.213)

90. Dunner DL: A Study Group: "Conceptual and methodological uncertainties in the biological provocation of panic attacks." Presented at the Annual Meeting, American College of Neuropsychopharmacology, Maui, Hawaii, December 9-13, 1985.
91. Lewy AJ, Sack RL, and Dunner DL: Three critical parameters for chronobiologically active light: intensity, wave length, and timing. Presented at the Annual Meeting, American College of Neuropsychopharmacology, Maui, Hawaii, December 9-13, 1985 (Abstracts p.117).
92. Reichler RJ, Hyde T, Sylvester C, and Dunner DL: Children at risk for anxiety disorders and depression. Presented at the Annual Meeting, American College of Neuropsychopharmacology, Maui, Hawaii, December 9-13, 1985 (Abstracts p.134).
93. Dager SR, Khan A, Comess K, Raisys V, and Dunner D: Catecholamine activity, autonomic arousal and mitral valve prolapse in anxious patients. Presented at the 41st Annual Meeting, Society of Biological Psychiatry, Washington, DC, May 7-11, 1986 (Abstracts p.106).
94. Cowley DS, Dager SR, and Dunner DL: Lactate-induced panic: effects of alprazolam treatment. Presented at the 41st Annual Meeting, Society of Biological Psychiatry, Washington, DC, May 7-11, 1986 (Abstracts p.131).
95. Dunner DL: Stability of bipolar II affective disorder. Presented at the 139th Annual Meeting of the American Psychiatric Association, May 10-16, 1986, Washington, DC (Abstracts p.162).

96. Cowley DS, Hyde TS, Dager SR, and Dunner DL: Lactate infusions: the role of baseline anxiety. Presented at the 139th Annual Meeting, American Psychiatric Association, May 10-16, 1985, Washington DC (New Research Abstract, p.23).
97. Cowley DS, Dager SR, and Dunner DL: Lactate infusions in different diagnostic groups. Presented at the 15th meeting of the Collegium Internationale Neuropsychopharmacologicum, San Juan, Puerto Rico, December 14-17, 1987.
98. Khan A, Cohen S, Chiles J, Hyde T, and Dunner DL: Therapeutic role of a psychiatric intensive care unit in acute psychosis. Presented at the 42nd Annual Meeting, Society of Biological Psychiatry, Chicago, IL, May 6-10, 1987 (Abstracts, p.37).
99. Dager SR, Cowley DS, Dorsa DM, and Dunner DL: Beta-endorphin response to lactate infusion. Presented at the 42nd Annual Meeting, Society of Biological Psychiatry, Chicago, IL, May 6-10, 1987 (Abstracts, p.190).
100. Khan A, Cohen S, Avery DH, and Dunner DL: Treatment options in psychotic depression. Presented at the 42nd Annual Meeting, Society of Biological Psychiatry, Chicago, IL, May 6-10, 1987 (Abstracts, p.301).
101. Khan A, Hyde T, and Dunner DL: Treatment response to placebo and IMI/DMI in outpatients with major depression. Presented at the 42nd Annual Meeting, Society of Biological Psychiatry, Chicago, IL, May 6-10, 1987 (Abstracts, p.302).
102. Dager SR, Cowley DS, Kenny M, and Dunner DL: NE response to lactate infusion in panic, depressed and control subjects. Presented at the 6th International Catecholamine Symposium, Jerusalem, Israel, June 14-19, 1987 (Abstracts, p.117).

103. Dager SR, Cowley DS, Kenny M, and Dunner DL: NE levels in panic patients differentiated by response to lactate infusion. Presented at the 6th International Catecholamine Symposium, Jerusalem, Israel, June 14-19, 1987 (Abstracts, p.188).
104. Dunner DL, Avery DH, Dager SR, and Khan A: Rolipram: A placebo-controlled trial in outpatients with major depressive disorder. Presented at the 6th International Catecholamine Symposium, Jerusalem, Israel, June 14-19, 1987 (Abstract s, p.119).
105. Dunner DL: The diagnosis and neurobiology of anxiety disorders. Presented at the Ninth World Congress of the International College of Psychosomatic Medicine, Sydney, Australia, August 30-September 4, 1987 (Abstracts, p.47).
106. Khan A and Dunner DL: Clinical predictors of placebo response in depressed outpatients. Presented at the 26th Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 7-11, 1987 (Abstracts, p.58).
107. Dager SR, Rainey JM, Dunner DL, Artru A, Kenny M, and Bowden D: Central effects of lactate infusion in a primate model. Presented at the 26th Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 7-11, 1987 (Abstracts, p.58).
108. Reichler RJ, McClellan J, and Dunner DL: Affective disorders presenting as attention deficit disorders in childhood. Presented at the 26th Annual Meeting, American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 7-11, 1987 (Abstracts, p.184).
109. Ward N, Whitney C, Avery D, and Dunner D: Caffeine's effects on mood and pain. Presented at the 43rd Annual Meeting, Society of Biological Psychiatry, Montreal, Canada, May 4-8, 1988. Abstracts p.68.

110. Ward N, Labbe RF, and Dunner D: Pyridoxine and iron states in depression. Presented at the 43rd Annual Meeting, Society of Biological Psychiatry, Montreal, Canada, May 4-8, 1988. Abstracts p.301.
111. Dunner DL, Avery DH, Dager SR, and Khan A: Rolipram: a placebo-controlled trial in outpatients with major depressive disorder. Presented at the XVI CINP Congress, Munich, August 15-19, 1988. Abstracts p.245.
112. Khan A, Dager S, and Dunner DL: Clinical and demographic features related to placebo and antidepressant response. Presented at the 44th Annual Meeting, Society of Biological Psychiatry, San Francisco, CA, May 4-8, 1989. Abstracts, pp.79A-80A.
113. Avery D, Khan A, Dager SR, Cox GB, and Dunner DL: Bright light treatment of winter depression: AM compared to PM light. Presented at the 44th Annual Meeting, Society of Biological Psychiatry, San Francisco, CA, May 4-8, 1989. Abstracts, p. 83A.
114. Dunner DL: Diagnosis and treatment of seasonal depression. Presented at the 142nd Annual Meeting, American Psychiatric Association, San Francisco, CA, May 6-11, 1989. Abstracts p.42.
115. Dunner DL, Colombo M, and Cox G: Assortative mating in affective disorders: an update. Presented at the First World Congress on Psychiatric Genetics, Cambridge, England, August 3-5, 1989 (Abstracts, p.5).
116. Dager SR, Khan A, Cowley DC, Avery D, Elder J, Roy-Byrne P, and Dunner DL: Clinical characteristics of placebo response among panic patients. Presented at the 28th Annual

Meeting, American College of Neuropsychopharmacology, Maui, HI, Dec. 10-15, 1989.  
(Abstracts P.183).

117. Khan A, Dager S, Cohen S, Avery DH, and Dunner DL: When is the onset of response to antidepressants? Presented at the 28th Annual Meeting, American College of Neuropsychopharmacology, Maui, HI, Dec. 10-15, 1989. (Abstracts P. 198).
118. Peselow ED, Dunner DL, and Fieve RR: The prophylactic effect of tricyclic antidepressants - a five year follow-up. Presented at the 28th Annual Meeting, American College of Neuropsychopharmacology, Maui, HI, 1989. Dec. 10-15, 1989. (Abstracts p.212).
119. Brown WA and Dunner DL (Co-Chairs): Placebo response in depression. Study Group - Presented at the 28th Annual Meeting, American College of Neuropsychopharmacology, Maui, HI, Dec. 10 -15, 1989. (Abstracts P.44).
120. Dunner DL, Colombo M, Cox G: Assortative mating in mood and anxiety disorders. Presented at the 17th Congress of Collegium Internationale Neuro-Psychopharmacologicum, Kyoto, Japan, Sept. 10-14, 1990. (Abstracts P.58).
121. Dager SR, Comess KA, Saal AK, Sisk EJ, Cowley DS, Avery DH and Dunner DL: Mitral valve prolapse and panic disorder; Clinical and biological characteristics. Presented at the 29th Annual Meeting, American College of Neuropsychopharmacology, San Juan, PR, Dec. 10-14, 1990. (Abstracts P. 124).
122. Dunner DL, Colombo M, Cox G: Assortative mating in mood and anxiety disorders. Presented at the 46th Annual Meeting, Society of Biological Psychiatry, New Orleans, LA, May 5-12, 1991. (Abstracts p. 150).

123. Avery D, Brengelmann G, Savage M, Dahl K, Punz P, Vitrello M, Dunner D, and Elmore S: Is the temperature setpoint elevated in depression? Presented at the 46th Annual Meeting, Society of Biological Psychiatry, New Orleans, LA, May 5-12, 1991. (Abstracts p. 168).
124. Wingerson D, Roy-Byrne P, Sullivan M, Cowley D, Dager S, and Dunner D: Personality and early drop-out from clinical trials. Presented at New Research, Annual Meeting of the American Psychiatry Assn, New Orleans, LA, May 12-16, 1991. (Abstracts p. 191).
125. Dunbar GC, and Dunner D: Optimal dose regimen for the new antidepressant paroxetine. Presented at the 5th World Congress of the World Federation of Societies of Biological Psychiatry, Florence, Italy, June 9-14, 1991. (Abstract: Biol Psychiatry 29:257S, 1991).
126. Dunner, DL and Dunbar GC: Reduced suicidal thoughts and behavior (suicidality) with paroxetine. Presented at the 30th Annual Meeting, American College of Neuropsychopharmacology, San Juan, PR, Dec 9-13, 1992 (Abstracts p. 227).
127. Avery DH, Bolte MA, Meyer M, Dager S, Wilson L, Dunner D, and Cox G: Dawn simulation treatment of winter depression: A controlled study. Presented at the 47th Annual Meeting of the Society of Biological Psychiatry, Washington DC, April 29-May 3, 1992. Biological Psychiatry 31: 183A, 1992 (Abstract).
128. Dunner DL, Tay LK: Diagnostic reliability of hypomania. Presented at the 47th Annual Meeting of Biological Psychiatry, Washington DC, April 29-May 3, 1992. Biological Psychiatry 31: 247A, 1992 (Abstract).

129. Dunner DL and Tay LK: Diagnostic reliability of hypomania. Presented at the Collegium Internationale Neuro-Psychopharmacologicum. Nice, France, June 28-July 2, 1992 (Abstracts p. 516B).
130. Wheadon DE, Bushnell WD, Pitts, CD and Dunner DL: Effect of response criteria, severity of illness, and duration of illness on placebo response in trial of two serotonin reuptake inhibitors. Presented at the 31st Annual Meeting, American College of Neuropsychopharmacology, San Juan, PR, Dec. 14-18, 1992 (Abstracts P. 195).
131. Shrivastava RK, Cohn D, Crowder C, Davidson J, Dunner DL, Feighner J, Kiev A, Patrick R: Double blind, long term safety and clinical acceptability study of venlafaxine and imipramine in outpatients with major depression. Presented at the 31st Annual Meeting, American College of Neuropsychopharmacology, San Juan, PR, Dec. 14-18, 1992 (Abstracts p. 202).
132. Dunner DL: Strategies for research in children and adolescents. Presented at the 48th Annual Meeting of the Society of Biological Psychiatry, San Francisco, CA May 19-23, 1993 (Abstracts p. 37A).
133. Sylvester C, Reichler RJ, Hyde TS, Drexler MA, and Dunner DL: Children at risk for panic disorder and/or depression. Presented at the 48th Annual Meeting of the Society of Biological Psychiatry, San Francisco, CA, May 19-23, 1993 (Abstracts p. 102A).
134. Dunner DL: Overview of current antidepressant treatment. Presented at the 146th Annual Meeting of the American Psychiatric Assn., San Francisco, CA, May 22-27, 1993 (Abstracts p. 36).

135. Dunner DL and Nelsen MR: Treatment resistant depression: Clinical characteristics. Presented at the 49th Annual Meeting, Society of Biological Psychiatry, Philadelphia, PA, May 18-22, 1994. Biological Psychiatry 35:617,1994 (Abstract).
136. Dunner DL: Bipolar disorder: Diagnostic revisions for DSM-IV. Presented at the Annual Meeting, American Psychiatry Association, Philadelphia, PA, May 21-26, 1994. Continuing medical education syllabus and scientific proceedings in summary form. American Psychiatric Association, Washington, DC, pg. 142, 1994.
137. Dunner DL and Tay LK: Diagnostic reliability of hypomania. Presented at the First International Conference on Bipolar Disorder, Pittsburgh, PA June 23-24, 1994. (Abstract p. 1).
138. Dunner DL and Schmaling KB: Treatment of dysthymia: Fluoxetine versus cognitive therapy. Presented at the 19th Collegium Internationale Neuro-Psychopharmacologicum Congress, Washington, DC, June 27-July 1, 1994. Neuropsychopharmacology 10, Supplement Part 2, p. 234S.
139. Dunner DL, Schmaling KB, Hendrickson HH, and Becker J: Treatment of dysthymia: Fluoxetine vs cognitive therapy. Presented at the 33rd Annual Meeting, American College of Neuropsychopharmacology, San Juan, PR, December 12-16, 1994 (Abstracts P. 106).
140. Dunner D. Diagnostic status of bipolar disorder. Presented at the 2nd International Conference on New Directions in Affective Disorders, Jerusalem, Israel, Sept. 3-8, 1995. (Abstract S-81)
141. Dunner D, Schmaling K, Hendrickson H, Becker J. Treatment of Dysthymia: Fluoxetine versus cognitive therapy. Presented at the 2nd International Conference on New Directions in Affective Disorder, Jerusalem, Israel, Sept. 3-8, 1995 (Abstract p.76).

142. Dunner DL and Feinman J: The effect of substance abuse on the course of bipolar disorder. Presented at the 34th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, PR, Dec 11-15, 1995 (Abstracts p.171).
143. Dunner DL and Feinman J: The effect of substance abuse on the course of bipolar disorder. Presented at the Annual Meeting of the Society of Biological Psychiatry. New York, NY, May 1-5, 1996. Biological Psychiatry 39:617, 1996.
144. Dunner DL and Feinman J: The effect of substance abuse on the course of bipolar disorder. Presented at the XXth Collegium international Neuropsychopharmacologicum Congress, Melbourne, Australia, June 23-27, 1996. European Neuropsychopharmacology 8(Suppl 3):183, 1996.
145. Dunner DL: Rapid cycling bipolar disorder: An Update. Presented at the XXth Collegium Internationale Neuropsychopharmacologicum Congress, Melbourne, Australia, June 23-27, 1996. European Neuropsychopharmacology 8(Suppl 3):84, 1996.
146. McCullough JP, Kornstein S, Klein D, Kocsis JH, Dunner DL, Koran L. Cognitive behavior therapy for chronic depression (CBT-CD): Combined national collaborative study. Presented at the 52nd Annual Meeting, Society of Biological Psychiatry, May 14-18, 1997, San Diego, CA. Biological Psychiatry 41:27S, 1997.
147. Dunner DL, Hendrickson HE, Bea CJ, Budech CB: Treatment of dysthymic disorder with venlafaxine. Presented at the 52nd Annual Meeting, Society of Biological Psychiatry, May 14-18, 1997, San Diego, CA. Biological Psychiatry 41: 92S, 1997.

148. Fava M, Dunner DL, Greist J, Hornig-Rohan M, Preskorn S, Trivedi M, Zajecka J, Cohen M, Wingard P. An open-label study of mirtazapine in depressed patients who failed treatment with an SSRI. Presented at the 52nd Annual Meeting, Society of Biological Psychiatry, May 14-18, 1997, San Diego, CA. Biological Psychiatry 41:96S.
149. Dunner DL, Hendrickson HE, Bea CJ, Budech CB: Treatment of dysthymic disorder with venlafaxine. Presented at the 6th World Congress of Biological Psychiatry, Nice, France, June 22-27, 1997. Biological Psychiatry 42:2542, 1997 (Abstract).
150. McCullough JP, Keller MB, Hirschfeld RMA, Russell JM, Dunner DL, Thase ME, Kocsis JH. Collaborative study of nefazodone and CBT-CD in chronically depressed patients. Presented at the 6th World Congress of Biological Psychiatry, Nice, France, June 22-27, 1997. Biological Psychiatry 42 1997.
151. Dunner DL, Schmaling KB, Hendrickson H, Becker J. Treatment of dysthymia: Fluoxetine vs. cognitive therapy. Presented at the Regional Meeting, World Psychiatric Association, Beijing China, Oct. 7-10, 1997 (Abstracts p. 32-33).
152. Dunner DL. Chronic depression: managing emerging bipolar symptoms. Presented at the 151<sup>st</sup> Annual Meeting. American Psychiatric Assn. Toronto, Canada, May 30-June 4, 1998. (Abstracts p. 291).
153. Dunner DL. Dysthymic Disorder. Presented at the 151<sup>st</sup> Annual Meeting, American Psychiatric Assn., Toronto, Canada, May 30-June 4, 1998. (Abstracts p. 322).
154. Fava M, Zajecka J, Trivedi MH, Dunner DL, Greist J, Cohen M. An open trial of mirtazapine in the treatment of depressed outpatients refractory to or intolerant of treatment

- with SSRIs. Presented at the 151<sup>st</sup> Annual Meeting, American Psychiatric Assn., Toronto, Canada, May 30-June 4, 1998.
155. Dunner DL, Hendrickson HE, Budech C, Bea C. Mirtazapine treatment of dysthymic disorder. Presented at the XXI<sup>st</sup> CINP Congress, Glasgow, Scotland, July 12-16, 1998 . (Abstracts p. 267). Int J Neuropsychopharmacology 2:Suppl 1, pS32, 1999.
  156. Layton ME, Dager SR, Friedman SD, Richards TL, Dunner DL, Posse S. Proton echo-planar spectroscopic imaging of brain metabolic changes in lactate-induced panic; effects of gabapentin treatment. Presented at the XXI<sup>st</sup> CINP Congress, Glasgow, Scotland, July 12-16, 1998.(Abstracts pg. 302.). Int J Neuropsychopharmacology 2:Suppl 1, pS75, 1999.
  157. Dager SR, Friedman S, Layton ME, Strauss W, Richards TL, Heide A, Aitru AA, Dunner DL, Posse S. Measurement of regional brain metabolic changes during lactate-induced panic by proton echo-planar spectroscopic imaging. Presented at the XXI<sup>st</sup> CINP Congress, Glasgow, Scotland, July 12-16, 1998. (Abstracts pg. 175.)
  158. Dunner DL. Selecting an antidepressant for the long-term treatment of depression. Presented at the 50<sup>th</sup> Institute of Psychiatric Services, Los Angeles, Oct. 2-6, 1998 (Abstracts p. 18-19).
  159. Kocsis JH, Dunner DL, Fawcett J, Hirschfeld R, Nemeroff C, Keller M, McCullough J, Rush AJ, Schatzberg A, Thase M. The Chronic Depression Study Group, Borian F, Jody D. Nefazodone HCL, CBT-CD and combination therapy for the acute treatment of chronic depression. Presented at the 37<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology. Las Croabas, Puerto Rico, Dec. 14-18, 1998 (Abstracts).

160. Dunner DL, Hendrickson HE, Budech C, Bea CB. Mirtazapine: Treatment of dysthymic disorder. Presented at the 37<sup>th</sup> Annual meeting of the American College of Neuropsychopharmacology. Las Croabas, Puerto Rico, Dec. 14-18, 1998 (Abstracts p. 275).
161. Dunner DL, Hendrickson HE, Budech C, Bea C. Mirtazapine: Treatment of dysthymic disorder. Presented at the 54<sup>th</sup> Annual Meeting, Society of Biological Psychiatry, Washington DC, May 13-15, 1999. Biological Psychiatry 45:p69S, 1999.
162. Dunner DL. Dysthymic disorder: Effect of euthymic periods on treatment outcome. Presented at 54<sup>th</sup> Annual Meeting, Society of Biological Psychiatry. Washington DC, May 13-15, 1999. Biological Psychiatry 45:p69S, 1999.
163. Dunner DL. Dysthymic disorder: SSRI treatment update. Presented at the American Psychiatric Association 1999 Annual meeting. Washington DC, May 15-20, 1999, Syllabus and Proceedings Summary, p225-226.
164. Dunner DL, Yang TW. Differential treatment response across chronic depression subtypes. Presented at the 38<sup>th</sup> Annual Meeting, American College of Neuropsychopharmacology, Acapulco, Mexico, Dec. 12-16, 1999 (Abstracts p.2).
165. Dunner DL, Dysthymic disorder: Effect of euthymic periods on treatment outcome. Presented at the 38<sup>th</sup> Annual Meeting, American College of Neuropsychopharmacology, Acapulco, Mexico, Dec. 12-16, 1999 (Abstracts p. 228).
166. Zajecka JM, Dunner DL, Hirschfeld RMA, Kornstein SG, Ninan PT, Rush AJ, Thase ME. Sexual function and satisfaction in the treatment of chronic depression with nefazodone, psychotherapy and their combination. Presented at the Annual Meeting, American

- Psychiatric Association, Chicago IL, May 13-18, 2000 (New Research Abstracts pp176-177).
167. Hirschfeld RMA, Dunner DL, Keitner GI, Klein DN, Koran LM, Kornstein SG, Markowitz JC. Treatment of psychosocial impairments in major depression. Presented at the Annual Meeting, American Psychiatric Association, Chicago IL, May 13-18, 2000 (New Research Abstracts p183).
  168. Shelton RC, Dunner DL, Halbreich U, Thase ME, Hirschfeld RMA, Gelenberg AJ, Keller MB. A placebo-controlled trial of St. John's wort in major depression. Presented at the Annual Meeting, American Psychiatric Association, Chicago IL, May 13-18, 2000 (New Research Abstracts p183).
  169. Russell JM, Crown WH, Arnow BA, Blalock JA, Dunner DL, Hirschfeld RMA, Kocsis JH, Koran LM, Kornstein SG, Manber R, Markowitz JC, Rush AJ, Thase ME, Trivedi MH, Berndt E, Finkelstein SN, Bonan FE. Economic aspects of nefazodone, CBASP, and their combination in the treatment of chronic depression. Presented at the XXII CINP congress. Brussels, July 9-13, 2000. *International Journal of Neuropsychopharmacology* 3,(Suppl): 5245, 2000.(Abstract) Poster.
  170. Hirschfeld RMA, Dunner DL, Lebowitz BD, Russell JM, Fulop G, Hylan TR: New Pharmaco-economic Findings, Presented at the 39<sup>th</sup> Annual Meeting of the American College of Neuropsychopharmacology, San Juan, PR, Dec 10-14, 2000. Study Group. Abstract p. 65.
  171. Hirschfeld RMA, Dunner DL et al. Psychosocial functioning in chronic major depression: Treatment with nefazodone, CBASP, and their combination. Presented at the 39<sup>th</sup>

Annual Meeting of the American College of Neuropharmacology, San Juan, PR, Dec 10-14, 2000.

172. Russell JM, Crown WH, Borian FE, Koran L, Trivedi MH, Arnow B, Markowitz J, Manber R, Berndt EJ, Finkelstein SN, Kocsis JH, Hirschfeld RMA, Rush AJ, Gelenberg AJ, Ling DCY, White AS, Dunner DL et al. Economic aspects of nefazodone, CBAS-Psychotherapy (CBASP), and their combination for the treatment of chronic major depression. Presented at the 39<sup>th</sup> Annual Meeting of the American College of Neuropharmacology, San Juan, PR, Dec 10-14, 2000. Poster abstract, p. 156.
173. Dunner DL Yang T. Depression subtypes. Presented at the Second International Congress on Hormones, Brain and Neuropsychopharmacology. Rhodos, Greece, 7/15-19, 2000. 23:(S2): S113 2000 (Poster Abstract).
174. Zajecka J, Dunner DL et al. Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, CBAS-Psychotherapy (CBASP) and their combination. Presented at the 39<sup>th</sup> Annual Meeting of the American College of Neuropharmacology, San Juan, PR, Dec 10-14, 2000. Poster abstract, p. 156. Post abstract p. 157.
175. Avery DH, Neumaier J, Roy-Byrne P, Dunner D, Tucker G, Claypoole K. TMS in the treatment of medication-resistant major depression. Presented at the 56<sup>th</sup> annual meeting, Society of Biological Psychiatry, New Orleans, LA, 5/3-5, 2001. Biological Psychiatry 49 8S:113S-114S, 2001.
176. Dunner DL. Ethnic and gender issues in the treatment of depression. Presented at the annual meeting, American Psychiatric Assn., New Orleans, LA, May 5-10, 2001. Abstracts p. 319.

177. Kocsis JH, Arnow BA, Borian FE, Dunner DL, Gelenberg AJ, Keitner GI, Klein DN. Continuation treatment with nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination for chronic depression. Presented at the annual meeting, American Psychiatric Assn., New Orleans, LA. May 5-10, 2001. New research abstracts, P. 105-106.
178. Dunner DL, Hendrickson H, Bea C, Budech CB. Dysthymic Disorder: Treatment With Citalopram. Presented at the 44<sup>th</sup> annual meeting, NCDEU. Phoenix, AZ May 28-31, 2001. Abstracts III-32.
179. Dunner DL. Diagnosis and management of chronic depression. Essential Psychopharmacology 21: 247-259, 2001 (interview).
180. Dunner DL, Hendrickson HE, Bea C, Budech C, Friedman S. Dysthymic disorder: treatment with citalopram. Presented at the 40<sup>th</sup> Annual Meeting, American College of Neuropsychopharmacology, Waikoloa, HI, Dec 9-13, 2001. (Abstract p. 135).
181. Dunner, DL. Diagnosis and treatment of dysthymia and double depression. Presented at the Annual Meeting of American Psychiatric Assn., Philadelphia, PA. May 18-23, 2002. Syllabus and scientific proceedings in summary form. American Psychiatric Assn, 2002, p. 74.
182. Dunner DL. Putting the pieces together: Treatments for the patient and the future. Presented at the Annual Meeting of American Psychiatric Assn., Philadelphia, PA, May 18-23, 2002. Syllabus and scientific proceedings in summary form. American Psychiatric Assn., 2002, p. 282.

183. Dunner D, Hendrickson HE, Bea C, Budech CB, Friedman S. Dysthymic disorder: treatment with citalopram. Presented at the XXIII CINP Congress, Montreal, Canada 6/23-27/2002. *Int J Neuropsychopharmacology* 5 (Suppl 1) S57, 2002.
184. Dunner DL, Mallincrodt C, Lu Y, Detke M. Duloxetine is effective in reducing anxiety symptoms associated with depression. Presented at the 41<sup>st</sup> Annual Meeting, American College of Neuropsychopharmacology, San Juan PR 12/8-12/2002. *Scientific Abstract* p. 133.
185. Dunner DL, Mallincrodt C, Lu Y, Detke MJ. Duloxetine is effective in reducing anxiety symptoms associated with depression. Presented at the 58<sup>th</sup> Annual Meeting, Society of Biological Psychiatry, San Francisco, CA. May 15-17, 2003. *Biological Psychiatry* 53: 193S, 2003.
186. Dunner DL. The clinical challenge of depression in bipolar disorder. Presented at the 156<sup>th</sup> Annual Meeting. American Psychiatric Assn. San Francisco, Calif. 5/17-22/2003. *Syllabus and Proceedings Summary*, p. 300.
187. Dunner DL, Amsterdam JD, Shelton RC, Hassman HA, Rosenthal M, Romano SJ. Adjunctive ziprasidone in treatment-resistant depression: A pilot study. Presented at New Research, American Psychiatric Assn, May 17-22, 2003. San Francisco, CA. (NR 238).
188. Dunner DL, Amsterdam JD, Shelton RC, Hassman HA, Rosenthal M, Romano SJ. Adjunctive ziprasidone in treatment-resistant depression: a pilot study. Presented at the 43<sup>rd</sup> Annual Meeting, NCDEU, Boca Raton, FL. May 27-30, 2003. *Abstracts* p. 123.

189. Dunner DL, Vo D, Friedman S. Treatment resistant bipolar disorder. Presented at the Fifth International Conference on Bipolar Disorder, Pittsburgh, PA. June 12-14, 2003. *Bipolar disorders 2003*; (Suppl 1):44.
190. Dunner DL, Amsterdam JD, Shelton RC, Hassman HA, Rosenthal M, Romano SJ. Adjunctive ziprasidone in treatment resistant depression: A pilot study. Presented at the 16<sup>th</sup> ECNP Congress, Prague, Czech Republic, Sept 20-24, 2003.
191. Dager, SR, Friedman SD, Parow AM, Demopulos CM, Stoll AL, Lyoo IK, Dunner DL, Renshaw PF. Brain chemical alterations in medication-free bipolar patients: evidence of mitochondrial dysfunction. Presented at the 42<sup>nd</sup> Annual Meeting, American College of Neuropsychopharmacology, San Juan, PR, December 7-11, 2003. Abstracts, p. 28.
192. Rapaport M, Dunner D, Caruso C, Loescher A, Bossie C, Turkoz L, Gharabawi G. Augmentation with risperidone in treatment resistant depression (ARISE - RD) trial: open-label results. Presented at the 42<sup>nd</sup> Annual Meeting, American College of Neuropsychopharmacology, San Juan, PR, December 7-11, 2003. Abstracts p. 96.
193. Dunner D, Russell JM, A long-term, prospective, naturalistic study of usual standard-of-care treatment in patients with treatment resistant depression. Presented at the 42<sup>nd</sup> Annual Meeting, American College of Neuropsychopharmacology, San Juan, PR, December 7-11, 2003. Abstracts p. 150.
194. Dimidjian SA, Hollon SD, Dobson KS, Schmaling KB, Kohlenberg RJ, Addis M, and Dunner DL. Behavioral activation, cognitive therapy, and medication for major depression. Methods and acute-phase outcomes. Presented at the 157<sup>th</sup> Annual Meeting, American Psychiatric Assn., NY, NY. May 1-6, 2004. Syllabus and Proceedings Summary p. 149.

195. Dobson KS, Hollon SD, Dimidjian SA, Schmaling KB, Kohlenberg RJ, Rizvi S, and Dunner DL. Production of treatment response. Presented at the 157<sup>th</sup> Annual Meeting, American Psychiatric Assn, NY, NY. May 1-6, 2004. Syllabus and Proceedings Summary p. 149.
196. Rizvi S, Dimidjian SA, Hollon SD, Dohsen KS, Schmaling KB, Kohlenberg RJ, and Dunner DL. Prediction of treatment response. Presented at the 157<sup>th</sup> Annual Meeting, American Psychiatric Assn., NY, NY. May 1-6, 2004. Syllabus and Proceedings Summary p. 149.
197. Dunner DL. A long-term, prospective, naturalistic study of usual standard-of-care treatment in patients with treatment-resistant depression. Presented at the 15<sup>th</sup> Annual Meeting, American Psychiatric Association, NY, NY. May 1-6, 2004. New Research Abstracts, p. 286.
198. Dunner DL. A long-term, prospective, naturalistic study of usual standard-of-care treatment in patients with treatment-resistant depression. Presented at the XXIV CINP Congress, Paris, France. June 20-24, 2004. *Int J Neuropsychopharmacology* 7(Suppl 1): S 163, 2004.
199. Dunner DL, D'Souza DN, Russell JM, Detke MJ. Duloxetine: infrequency of treatment-induced hypomania in subjects with major depression. Presented at the XXIV CINP Congress. Paris, France. June 20-24, 2004. *Int J Neuropsychopharmacology*. 7 (Suppl 1): S 352, 2004.
200. Dunner DL. Discerning differences in antidepressants: clinical trial design, meta-analysis, and outcomes interpretation. Presented at the 17<sup>th</sup> European Neuropsychopharmacology Congress, Stockholm, Sweden, October 12, 2004, *Journal of European Neuropsychopharmacology*, 14, (Supp 3), pp S404-S405, 2004.

201. Dunner DL, Amsterdam JD, Shelton RC, Romano SJ and Loebel A. Adjunctive Ziprasidone in treatment-resistant depression: randomized, double-blind, 8-week pilot study. Presented at the 43<sup>rd</sup> Annual Meeting, ACNP, San Juan P.R. December 12-16, 2004. *Neuropsychopharmacology*, 29 (Suppl 1): S99, 2004.
202. Keller, M, Kocsis J, Kornstein S, Rothschild A, Shelton R, Trivedi M, Ninan P, Gelenberg A, Dunner D, Hirschfeld R, Schatzberg A, Thase M, Benattia I, Del Greco F. Comparing the efficacy of venlafaxine XR and fluoxetine for acute, continuation, and maintenance therapy in recurrent unipolar major depression. Presented at the 43<sup>rd</sup> Annual Meeting, ACNP, San Juan, P.R. December 12-16, 2004. *Neuropsychopharmacology* 29 (Suppl 1): S148, 2004.
203. Dunner DL, Amsterdam JD, Shelton RC, Romano SJ and Loebel A. Adjunctive Ziprasidone in treatment-resistant depression: randomized, double-blind, 8-week pilot study. Presented at the 60<sup>th</sup> Annual Meeting, Society of Biological Psychiatry. Atlanta GA. May 18-21, 2005. *Biological Psychiatry* 57; 8S: 92S, 2005.
204. Bader CD, Dunner DL. Clinical characteristics of bipolar disorder not otherwise specified in relation to the bipolar spectrum. Presented at the 60<sup>th</sup> Annual Meeting, Society of Biological Psychiatry, Atlanta GA. May 18-21, 2005. *Biological Psychiatry* 87; 85:92S, 2005
205. Dunner DL, Amsterdam JD, Shelton RC, Romano SJ and Loebel A. Adjunctive Ziprasidone in treatment-resistant depression: randomized, double-blind, 8-week pilot study. Presented at the Annual Meeting, American Psychiatric Assn at Atlanta, Georgia May 21-26, 2005. *New Research* p 57.

206. Dunner DL. Influence of co-morbidity on the treatment of depression. Presented at the 158<sup>th</sup> Annual Meeting, American Psychiatric Association. Atlanta GA. May 21-26, 2005. Syllabus and Proceedings Summary, p. 50.
207. Bader CD, Dunner DL. Clinical characteristics of bipolar disorder not otherwise specified in relation to the bipolar spectrum. Presented at the 6<sup>th</sup> International Conference on Bipolar Disorders, Pittsburgh PA, June 26-28, 2005. *Bipolar Disorders* 7 (Supp 2): 30, 2005.
208. Dunner DL. A two-year longitudinal study of adjunctive vagus nerve stimulation for patients with treatment-resistant depression. Presented at the 18<sup>th</sup> ECNP Congress, Amsterdam, The Netherlands, Oct 22-26, 2005. *European Psychopharmac* 15 (Suppl 3): S401, 2005.
209. Dunner DL, Amsterdam JD, Shelton RC, Loebel A. Adjunctive ziprasidone for resistant depression: 8 week pilot study. Presented at the 18<sup>th</sup> ECNP Congress, Amsterdam, The Netherlands, Oct 22-26, 2005. *European Psychopharmac* 15 (Suppl 3): S444, 2005.
210. Dunner DL, Canuso CM, Bossie CA, Zhu Y. Underdiagnosis of psychotic symptoms in patients with bipolar mania. Presented at the 44<sup>th</sup> Annual Meeting, American College of Neuropsychopharmacology, Waikoloa HI, Dec 11-15, 2005, *Neuropsychopharmacology* 30, Suppl 1, S108, 2005.
211. Brown E, Dunner D, Adams D, Degenhardt E, Tohen M, Williamson D, Houston J. Olanzapine/fluoxetine combination versus lamotrigine in the long-term treatment of bipolar I depression. Presented at the 44<sup>th</sup> Annual Meeting, American College of Neuropsychopharmacology, Waikoloa HI, Dec 11-15, 2005, *Neuropsychopharmacology* 30, Suppl 1, S108, 2005.

212. Brown E, Dunner D, Adams D, Degenhardt E, Tohen M, Williamson D, Houston J. Olanzapine/fluoxetine combination versus lamotrigine in the long-term treatment of bipolar I depression. Presented at the 61<sup>st</sup> annual meeting, Society of Biological Psychiatry, Toronto, Canada, May 18-20, 2006, *Biological Psychiatry* 59, Suppl 8, S25, 2006.
213. Canuso CM, Bossie CA, Youssef E, Zhu Y, Dunner DL. Identification and treatment of psychotic symptoms in patients with bipolar mania. . Presented at the 61<sup>st</sup> annual meeting, Society of Biological Psychiatry, Toronto, Canada, May 18-20, 2006, *Biological Psychiatry* 59, Suppl 8, S180, 2006.
214. Dunner DL. Definitions and clinical characteristics of treatment-resistant depression. Presented at the 159<sup>th</sup> Annual Meeting, American Psychiatric Association, Toronto, Canada, May 20-25, 2006. *Syllabus and Proceedings Summary* 12-13.
215. Michelson D, Adler AA, Amsterdam JD, Dunner DL, Nierenberg AA, Reimherr FW, Schatzberg AF. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. Presented at the 159<sup>th</sup> Annual Meeting, American Psychiatric Association, Toronto, Canada, May 20-25, 2006. *Syllabus and Proceedings Summary* 74.
216. Brown E, Dunner D, Adams D, Degenhardt E, Tohen M, Williamson D, Houston J. Olanzapine/fluoxetine combination versus lamotrigine in the long-term treatment of bipolar I depression. Presented at the 159<sup>th</sup> Annual Meeting, American Psychiatric Association, Toronto, Canada, May 20-25, 2006. *New Research* 189.
217. Dunner DL, Bossie CA, Youssef E, Zhu Y, McLemoreBS, Canuso CM. Identification and treatment of psychotic symptoms in patients with bipolar mania. Presented at the 159<sup>th</sup>

- Annual Meeting, American Psychiatric Association, Toronto, Canada, May 20-25, 2006.  
New Research 207.
218. Dunner DL, Rush AJ, Russell JM, Burke M, Woodward S, Wingard P, Allen J. Prospective, long-term, multicenter study of the naturalistic outcomes of treatment-resistant depression. Presented at the 159<sup>th</sup> Annual Meeting, American Psychiatric Association, Toronto, Canada, May 20-25, 2006. New Research 208
  219. Keller MB, Yan B, Thase ME, Dunner D, Trivedi MH, Rothschild AJ, Kornstein SG. Recurrence prevention: Efficacy of two years of maintenance treatment with venlafaxine XR in patients with recurrent unipolar major depression. Presented at the 159<sup>th</sup> Annual Meeting, American Psychiatric Association, Toronto, Canada, May 20-25, 2006. New Research 528.
  220. Dunner DL. A review of the pilot, pivotal, and comparison trials of Vagus Nerve stimulation (VNS) for treatment resistant depression (TRD). Presented at the XXV Congress, CINP, Chicago, IL, July 9-13/2006. *Int J Neuropsychopharmacology* 2006; 9 (Suppl 1):S89.
  221. Keller M, Yan B, Dunner D, Ferguson J, Friedman E, Gelenberg A, Hirschfeld R, Kocsis J, Kornstein S, Nemeroff C, Ninan P, Rothschild A, Schatzberg A, Shelton, R, Thase M, Trivedi M, Zajecka J, Ahmed S, Musgnung J, Pedersen R. An analysis of recurrence prevention with venlafaxine XR in patients with recurrent unipolar major depression: a two-year maintenance treatment study. Presented at the XXV Congress, CINP, Chicago, IL, July 9-13/2006. *Int J Neuropsychopharmacology* 2006; 9 (Suppl 1):S184.
  222. Keller M, Yan B, Dunner D, Ferguson J, Friedman E, Gelenberg A, Hirschfeld R, Kocsis J, Kornstein S, Nemeroff C, Ninan P, Rothschild A, Schatzberg A, Shelton, R, Thase M, Trivedi M, Zajecka J, Ahmed S, Musgnung J, Parker-Zavod E, Pedersen R. A placebo-controlled trial of venlafaxine XR in patients with recurrent unipolar major depression to

- assess recurrence prevention. Presented at the XXV Congress, CINP, Chicago, IL, July 9-13/2006. *Int J Neuropsychopharmacology* 2006; 9 (Suppl 1):S233.
223. Dunner DL, Lee J. Anxiety co-morbidity in bipolar disorders. Presented at the 2<sup>nd</sup> Biennial Conference of the International Society of Bipolar Disorders, Edinburgh, Scotland, Aug 2-4, 2006. *Bipolar Disorders* 2006;8(Suppl 1):17.
224. Dunner DL, Canuso CM, Bossie CA, Pandina GJ, Zhu Y, Kujawa M. An evaluation of psychotic symptoms in patients with bipolar mania. Presented at the 2<sup>nd</sup> Biennial Conference of the International Society of Bipolar Disorders, Edinburgh, Scotland, Aug 2-4, 2006. *Bipolar Disorders* 2006;8(Suppl 1):31.
225. Brown E, Dunner DL, Adams DH, Degenhardt EL, Tohen M, Williamson DJ, Houston J. Olanzapine/fluoxetine combination versus lamotrigine in the long-term treatment of bipolar I depression. Presented at the 2<sup>nd</sup> Biennial Conference of the International Society of Bipolar Disorders, Edinburgh, Scotland, Aug 2-4, 2006. *Bipolar Disorders* 2006;8(Suppl 1):39.
226. Dunner DL. Suicide in bipolar disorders. Presented at the 6<sup>th</sup> Annual Meeting of International College of Geriatric Psychoneuropharmacology, Hiroshima, Japan, Oct 3-6, 2006. (Abstracts p. 62.)
227. Dunner DL, Kornstein S, Whitmeyer V, Meyers A, Mallinkrodt C, Wohlreich M, Hollandbeck M, Greist J. Effects of initial dosing strategies of duloxetine on tolerability and efficacy in patients with major depressive disorder. Presented at the 45<sup>th</sup> Annual Meeting, American College of Neuropsychopharmacology, Hollywood, FL, Dec 3-7, 2006. *Neuropsychopharmacology* 2006; 31:106S.

228. Avery DH, Holtzheimer PE, Fawaz W, Russo J, Neumaier J, Dunner D, Claypool K, Haynor, D, Wajdik C, Roy-Byrne P. Transcranial magnetic stimulation reduces pain in patients with major depression: A sham-controlled study. Presented at the 62<sup>nd</sup> annual meeting of the Society of Biological Psychiatry, San Diego, CA May 17-19, 2007. *Biol Psychiatry* 2007; 61;187S-188S .
229. Dunner DL (chair), Blier P, Keller MB, Pollack MH, Thase ME, Zajecka JM. Preventing recurrent depression: Long-term treatment for major depressive disorder. CD produced for the CME Institute, *J Clin Psychiatry*, 2007.
230. Schatzberg AF, Friedman ES, Rothschild AJ, Trivedi MH, Dunner DL, Gelenberg AJ, Ninan P, Shelton RC, Zajecka JM, Ahmed S, Musgnung J, Pederson R. Prevalence of pain and impact on treatment outcomes in patients with recurrent depressive disorder. Poster presented at the 46<sup>th</sup> annual meeting, American College of Neuropsychopharmacology, Boca Raton, Fl, Dec 9-13,2007 (Abstract from Poster session 1).
231. Dunner DL. Hypomania: Some concerns for DSM-V. Presented at the 3<sup>rd</sup> Biennial Conference of the International Society of Bipolar Disorders, Delhi-Agra India, Jan 27-30, 2008. *Bipolar Disorders* 2008;10 (Suppl 1): 4.
232. Dunner DL. New insights into bipolar disorder using novel imaging techniques (Symposium Overview). Presented at the International Society for Affective Disorders 4<sup>th</sup> Biennial Conference, Cape Town, South Africa March 14-17, 2008. *J Affective Disorders* 2008; 107 (Suppl 1): S49.
233. Dunner D, Bossie C, Turkoz I, Canuso C. Paliperidone extended-release (ER) in patients with schizoaffective disorder presenting with manic, mixed-manic or depressive

- symptomatology. Presented at the 48<sup>th</sup> annual meeting, American College of Neuropsychopharmacology, Ft. Lauderdale, FL, Dec 6-10, 2009 (Dec 8, poster 64).
234. Demitrack M, Dunner D. Methodological issues associated with the introduction of a device-based treatment into clinical psychiatry: evaluating patterns of use in a naturalistic clinical setting. Presented at the 48<sup>th</sup> annual meeting, American College of Neuropsychopharmacology, Ft. Lauderdale, FL, Dec 6-10, 2009 (Poster).
235. Dunner DL, Bossie CA, Turkoz I, Canuso CM. Paliperidone extended-release (ER) in patients with schizoaffective disorder presenting with manic or depressive symptomatology. Presented at the 5<sup>th</sup> Biennial conference, International Society for Affective Disorders, Vancouver, Canada, April 16-19, 2010. *J Affect Dis* 2010(Suppl 1):S61.(Poster)
236. Dunner DL, Laubmeier K, Manos G, Forbes RA, Baker RA. Effectiveness of adjunctive aripiprazole is not dependent on antidepressant therapy history: Pooled data from three clinical trials (CN138-139, CN138-163, CN138-165). Presented at the 49<sup>th</sup> Annual Meeting, American College of Neuropsychopharmacology, Miami Beach, FL, Dec 5-9, 2010 (Poster).
237. Demitrack, MA, Aaronson, S, Boyadjis T, Brock DG, Carpenter L, Cook I, Dunner D, Janicak PG, Lanocha K, Solvason B. A naturalistic, pragmatic clinical trial of the use of TMS in the Treatment of major depression. Presented at the 66<sup>th</sup> Annual Meeting of the Society of Biological Psychiatry, San Francisco, Ca, May 12-14, 2011 *Biological Psychiatry* 2011, 69S: 276S. (Poster).
238. Demitrack MA, Janicak PG, Carpenter LL, Brock DG, Bonneh-Barkay D, Dunner DL. A multisite, longitudinal, naturalistic observational study of transcranial magnetic stimulation (TMS) for major depression in clinical practice. Presented at the 68<sup>th</sup> Annual Scientific

Convention and Meeting, Society of Biological Society, San Francisco, CA May 16-18, 2013. *Biological Psychiatry* 2013;73 (Suppl 9S): 316S (Poster).

239. Dowd SM, Philip NS, Dunner DL, Aaronson ST, Brock DG, George MS. A randomized pilot study of maintenance Neurostar transcranial magnetic stimulation (TMS) in patients with major depression. Anxiety and Depression Association of America Annual Meeting, April 11, 2015, Miami, FL.
240. Carpenter L, Philip N, Dunner D, Dowd S, Aaronson S, Demitrack M, Hovav S, Janicak P, George M. Can medication free, treatment-resistant depressed patients who initially responded to TMS be maintained off medications? A prospective, 12-month multisite randomized pilot study. Presented at the 54<sup>th</sup> Annual meeting, American College of Neuropsychopharmacology, Hollywood, FL, December 6-10, 2015 ( Poster).

David L. Dunner

March 10, 2016

